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A B S T R A C T
Background
Neuraminidase inhibitors (NI) are recommended for use against influenza and its complications in inter-pandemic years and during
pandemics.
Objectives
To assess the effects of NIs in preventing and treating influenza, its transmission, and its complications in otherwise healthy adults, and
to estimate the frequency of adverse effects.
Search strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2009, issue 3) which contains the
Acute Respiratory Infections Group’s Specialised Register, MEDLINE (1950 to August 2009) and EMBASE (1980 to August 2009).
Selection criteria
Randomised controlled trials (RCTs) or quasi-randomised placebo-controlled trials of NIs in healthy adults exposed to naturally
occurring influenza.
Data collection and analysis
Two review authors independently applied inclusion criteria, assessed trial quality, and extracted data. We structured the comparisons
into prophylaxis, treatment, and adverse events, with further subdivision by outcome and dose.
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Main results
We identified four prophylaxis, 12 treatment and four post-exposure prophylaxis trials. In prophylaxis compared to placebo, NIs had
no effect against influenza-like illnesses (ILI) (risk ratio (RR) ranging from 1.28 for oral oseltamivir 75 mg daily to 0.76 for inhaled
zanamivir 10 mg daily). The efficacy of oral oseltamivir against symptomatic influenza was 76% (at 75 mg daily), and 73% (at 150 mg
daily). Inhaled zanamivir 10 mg daily performed similarly. Neither NI had a significant effect on asymptomatic influenza. Oseltamivir
induced nausea (odds ratio (OR) 1.79, 95% CI 1.10 to 2.93). Oseltamivir for post-exposure prophylaxis had an efficacy of 58% and
84% in two trials for households. Zanamivir performed similarly. The hazard ratios for time to alleviation of symptoms were in favour
of the treated group 1.20 (1.06 to 1.35) for oseltamivir and 1.24 (1.13 to 1.36) for zanamivir. Because of the exclusion of a review
of mainly unpublished trials of oseltamivir, insufficient evidence remained to reach a conclusion on the prevention of complications
requiring antibiotics in influenza cases (RR 0.57, 95% CI 0.23 to 1.37). Analysis of the US FDA and Japan’s PMDA regulators’
pharmacovigilance dataset, revealed incomplete reporting and description of harms preventing us from reaching firm conclusions on
the central nervous system toxicity of neuraminidase inhibitors.
Authors’ conclusions
Numerous inconsistencies detected in the available evidence, followed by an inability to adequately access the data, has undermined
confidence in our previous conclusions for oseltamivir. Independent RCTs to resolve these uncertainties are needed.
P L A I N L A N G U A G E S U M M A R Y
Influenza is an acute infection of the airways and the whole body, caused by a virus
Influenza symptoms include fever, headache and cough. Serious complications such as pneumonia can also occur. This review of
trials found that neuraminidase inhibitors (Nls) such as zanamivir (Relenza) and oseltamivir (Tamiflu) are effective in preventing
(’prophylaxis’) and treating the symptoms of influenza. They do not prevent infection or stop influenza viruses leaving the nose. Because
the review authors could not verify the content of a Roche-sponsored review of 10 randomised trials (eight of which were unpublished),
it was excluded. This changes the conclusions as there now is insufficient evidence to say whether NIs prevent complications such
as pneumonia. Oseltamivir causes nausea, vomiting and retching while zanamivir causes diarrhoea but the full picture on the drugs’
toxicity cannot be reconstructed as the regulators’ data are incomplete and too generic. There is no randomised controlled trial evidence
to tell us whether NIs are or are not effective against pandemic influenza. Trials are urgently needed to test whether NIs are more
effective than symptomatic treatment and hygiene and barrier measures to interrupt influenza transmission in healthy adults.
B A C K G R O U N D
Description of the condition
Influenza is an acute, usually benign and self-limiting infection of
the upper airways and at times affects the whole body.
Description of the intervention
In recent years a new generation of antiviral compounds has
been developed. These compounds, known collectively as neu-
raminidase inhibitors (NIs) are nebulised zanamivir (Relenza, (for-
merly knownasGG167) developedbyGlaxoWellcomePLC (UK)
and oral oseltamivir (Tamiflu, formerly known as RO 64-0796
or GS 4104) co-developed by Gilead Sciences Inc (Foster City,
CA, USA) andHoffman La Roche Ltd (Basel, Switzerland). Other
NIs are still under development for parenteral or long acting use
(Hayden 2009).
How the intervention might work
NIs act by inhibiting the release of virions from the infected cell,
neuraminidase being essential for both viral entry and exit from
the target cell. The World Health Organization (WHO) encour-
aged member countries to use antivirals in influenza “inter-pan-
demic periods”. The rationale given is as follows: “wide scale use
of antivirals and vaccines during a pandemic will depend on famil-
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iarity with their effective application during the inter-pandemic
period. The increasing use of these modalities will expand capac-
ity and mitigate the morbidity and mortality of annual influenza
epidemics. Studies conducted during the inter-pandemic period
can refine the strategies for use during a pandemic” (WHO 2005).
The European Medicines Agency (EMEA) took a different line,
identifying NIs (especially oseltamivir) as compounds with a com-
plementary effect to vaccines to be used in an influenza pandemic
(EMEA 2005) for treatment of index cases and influenza prophy-
laxis in key personnel (police, fire brigade, healthcare workers).
Why it is important to do this review
The use of NIs has increased dramatically with the spread of the
A/H1N1 pandemic beginning in April 2009, a novel and poten-
tially serious infection. Partly because of the rise in amantadine/ri-
mantadine resistance coupled with the lack of an effective vaccine,
NIs became a widespread public health intervention. Their use
for early containment and interruption was also recommended in
many pandemic plans, and the WHO had previously encouraged
member countries to gain experience with them.
Although several systematic reviews of the effects of NIs are avail-
able, none are up-to-date or evaluate the potential role of NIs in an
influenza pandemic, where high viral load and high transmission
appear to be the norm; nor do they systematically investigate the
potential harms of NIs (Burch 2009; Burls 2002; Cooper 2003;
Jefferson 2000; Tappenden 2009; Turner 2003). In this context,
trade-off between dosage and adverse event profile in prophylaxis,
activity against influenza infection regardless of symptoms (symp-
tomatic and asymptomatic influenza) and viral excretion through
body fluids become important (Ward 2005).
In addition, our previous Cochrane review updates (Jefferson
2006; Jefferson 2009c) summary of the evidence on the effects
of oseltamivir on lower respiratory tract complications was chal-
lenged by Hayashi through the public Cochrane reviews feedback
mechanism (Feedback 1). In updating our review, we addressed
these additional issues.
O B J E C T I V E S
1. To assess the efficacy and effectiveness of NIs in preventing
cases and complications of influenza (prophylaxis) in healthy
adults.
2. To assess the efficacy and effectiveness of NIs in shortening
or reducing the impact and complications of influenza
(treatment) in healthy adults.
3. To assess the effectiveness of NIs in interrupting the spread
of influenza virus.
4. To estimate the frequency of adverse effects associated with
NI administration in healthy adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Any RCT or quasi-RCT comparing oral oseltamivir and/or
zanamivir in humans with placebo, control antivirals or no in-
tervention or comparing doses or schedules of oseltamivir and/or
zanamivir. Studies assessing prophylaxis or treatment from expo-
sure to naturally occurring influenza only were considered.
Types of participants
Individuals with no known pre-existing chronic pathology known
to aggravate the course of influenza. In keeping with our objective
of reviewing evidence onhealthy adults, we only considered studies
in which no less than 75% of the subjects were aged 14 to 60 to
exclude older subjects who are at higher risk of complications.
Types of interventions
Oseltamivir and/or zanamivir as prophylaxis and/or treatment for
influenza (efficacy) or for influenza-like illness (ILI/effectiveness).
Types of outcome measures
Primary outcomes
1. Mortality.
2. Hospitalisation and complications.
3. Harms.
4. Drug resistance.
Secondary outcomes
1. Symptom relief.
2. Viral excretion.
3. Interruption of transmission.
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Search methods for identification of studies
Electronic searches
For this 2009 update we ran update searches for effectiveness stud-
ies and conducted a separate search for adverse effects studies. In
previous versions of this review no specific searches for adverse
effects were undertaken. We relied instead on information gath-
ered from the RCTs and quasi-RCTs identified in the effectiveness
searches. Growing concerns about harms caused us to broaden our
approach for this update. We conducted separate, specific adverse
effects searches based on the work of Cochrane Adverse Effects
Methods Group. As these searches had not been carried out pre-
viously they were run over all years.
To identify effectiveness studies we searched the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) (The Cochrane Li-
brary 2009, issue 3) which contains the Acute Respiratory In-
fections Group’s Specialised Register; MEDLINE (2008 to July
2009); and EMBASE (2008 to July 2009). See Appendix 3 for
dates of previous effectiveness searches. We also searched for post-
marketingpharmacovigilance data and comparative safety cohorts.
The following search strategy was used in MEDLINE in conjunc-
tion with the Cochrane highly sensitive search strategy for identi-
fying RCTs (Lefebvre 2008). The same strategy was used to search
CENTRAL and the terms were adapted to search EMBASE. See
Appendix 1 for the EMBASE search strategy.
MEDLINE (OVID)
1 exp INFLUENZA/
2 influenza$.mp.
3 or/1-2
4 neuraminidase inhibitor$.mp.
5 oseltamivir.mp.
6 zanamivir.mp.
7 GS4071.mp.
8 or/4-7
9 3 and 8
To identify adverse effects studies we searched the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) (The Cochrane Li-
brary 2009, issue 3), MEDLINE (Ovid) (1950 to July Week 5
2009) and EMBASE (Ovid) (1980 to 2009 Week 31).
The following search strategy (based on the work of Golder 2006)
was used inMEDLINE.The search strategywas adapted forCEN-
TRAL and EMBASE (Appendix 4).
MEDLINE (Ovid)
1 exp Oseltamivir/
2 exp Zanamivir/
3 (oseltamivir or zanamivir or GS4071 or tamiflu or relenza).tw.
4 neuraminidase inhibitor*.tw.
5 1 or 2 or 3 or 4
6 (ae or to or po or co).fs.
7 (safe or safety).tw.
8 side effect*.tw.
9 ((adverse or undesirable or harms* or serious or toxic) adj3 (ef-
fect* or reaction* or event* or outcome*)).tw.
10 exp Product Surveillance, Postmarketing/
11 exp Adverse Drug Reaction Reporting Systems/
12 exp Clinical Trials, Phase IV as Topic/
13 exp Poisoning/
14 exp Substance-Related Disorders/
15 exp Drug Toxicity/
16 exp Abnormalities, Drug-Induced/
17 exp Drug Monitoring/
18 exp Drug Hypersensitivity/
19 (toxicity or complication* or noxious or tolerability).tw.
20 exp Case-Control Studies/
21 exp Cohort Studies/
22 or/6-21
23 5 and 22
Searching other resources
We also checked the bibliographies of other systematic reviews
of the topic (Burch 2009; Burls 2002; Cooper 2003; Tappenden
2009; Turner 2003). No language or publication restrictions were
applied. Please refer to Appendix 2 for a glossary of terms.
Data collection and analysis
Selection of studies
For this 2009 update, two review authors (ED, TOJ) indepen-
dently read all titles and studies retrieved in the search and applied
inclusion criteria. Disagreements were resolved by discussion with
a third review author (CDM).
Data extraction and management
The following data were extracted onto standard forms, checked
and recorded:
Characteristics of participants
1. Number of participants.
2. Age, gender, ethnic group, risk category.
Characteristics of interventions
1. Type of NI, type of placebo, dose, treatment or prophylaxis
schedule, length of follow up (in days).
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Characteristics of outcome measures
1. Number and severity of influenza cases in NI and placebo
groups.
2. Concentration of influenza viruses excreted by nasal
mucous.
3. Adverse effects: presence and type.
4. Date of trial.
5. Location of trial.
6. Funder of trial (specified, known or unknown).
7. Publication status.
No new data were extracted for this 2009 update. Twenty-eight
studies were retrieved and 29 studied were excluded.
Assessment of risk of bias in included studies
In the previous publication of this review (Jefferson 2009c) assess-
ment of methodological quality for RCTs was carried out using
the risk of bias tool, as recommended in the Cochrane Handbook
of Reviews of Interventions (Higgins 2008a). We assessed studies
according to adequacy of methods of generation of the allocation
sequence, allocation concealment and blinding and dealing with
losses to follow up. When there was disagreement among the re-
view authors (TOJ, DR) on the quality of a trial, a third review
author (VD) arbitrated. No new studies were included in this up-
dated review.
In this update, there were no new trials to assess. One study (Kaiser
2003), a review of 10 other trials, was re-assessed, and found to be
ineligible. A full discussion can be found in Appendix 5 (Doshi
2009).
Measures of treatment effect
We used random-effects methods to compare dichotomous out-
comes (RR for efficacy and OR for safety), therefore estimates
meta-analysed over multiple trials are average treatment effects.
Where hazard ratios were not provided, we converted the ratio of
medians of treatment groups into (log) hazard ratios (estimating
the variance of these) (Parmar 1998) to enable meta-analysis of
time to event outcomes.
Assessment of heterogeneity
We assessed heterogeneity used the I2 statistic and Chi2 test. Due
to the low power of the Chi2 test we assumed P < 0.1 to indicate
evidence of heterogeneity.
Assessment of reporting biases
See Appendix 5.
Data synthesis
We structured the comparisons into prophylaxis, treatment and
adverse events and further subdivided them by outcome and dose.
The RRs of events comparing prophylaxis and placebo groups
from the individual trials were combined using random-effects
models to include between-trial variability.
Subgroup analysis and investigation of heterogeneity
We planned to investigate possible reasons for heterogeneity using
variables such as trial quality and trial sponsorship (industry versus
other).
Sensitivity analysis
We carried out a sensitivity analysis of methods used compar-
ing our results obtained using the fixed-effect and random-effects
models. In the prophylaxis trials efficacy was derived as 1-RR (risk
ratio) x 100 or the RR when not significant. Odds ratios (OR)
were used to estimate association of adverse effects with exposure
to antivirals. In the treatment trials, analysis of “time to allevia-
tion of symptoms” and “time to return to normal activity” out-
comes provided some difficulty due to inconsistent and non-stan-
dard reporting in the majority of the trial reports. Most reports
described these outcomes in terms of medians for each treatment
group. However, standard reporting in a meta-analysis requires
these outcomes to be expressed as (log) hazard ratios. If it is as-
sumed that the treatment effect is constant over time (as seems
reasonable) then the ratio of the medians can be used to estimate
the hazard ratio. To estimate the variance of the log hazard ratio,
the method given by Parmar et al was used (Parmar 1998). The
number of events was estimated from survival curves when these
were available or, when they were not available, assumed to be all
patients completing the trial providing follow up was sufficiently
long enough for this to be a reasonable assumption.
In one study (Boivin 2000) followupwas possibly not long enough
for this to be a reasonable assumption, however this was a small
trial (27 participants in total) and follow up was sufficiently long
enough for more than 90% of the patients to be expected to reach
the endpoint. The impact of including this trial in the overall
analysis is likely to be negligible. As a check to see if the estima-
tion methods used are accurate, one study (Makela 2000) pro-
vided both hazard ratios and medians. The two methods provided
identical results for the intention-to-treat (ITT) population and
similar results for the influenza-positive population. The random-
effects inverse variance method was used for the meta-analysis of
the log hazard ratio. Two studies presented nasal viral titre data as
medians and ranges (Nicholson 2000; Treanor 2000). The data
were converted into means and standard deviations (SDs) to be
consistent with other studies and allowmeta-analysis. Means were
converted directly from the medians as both are measures of cen-
tral tendency and should be similar for approximately symmetrical
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data. The range was converted to a SDusing themethod described
by Hurlburt 1994. The inter-quartile range (IQR) was converted
to SD by multiplying by 68/50 (as 50% of the data is contained
within the IQRwhile +/- 1 SD contains 68% of the data providing
it is approximately normally distributed) then dividing by 2 (to
estimate 1 SD).
We also searched for evidence of harms more widely, including
submitting a Freedom of Information Act request to the US Food
and Drug Administration (FDA) for all data on the harms of
oseltamivir and zanamivir, and pursuing authors of some papers
and manufacturers to obtain raw data (FDA 2009b)
We were unable to meta-analyse the same outcomes reported by
Kaiser et al (Kaiser 2003) because the data for those outcomes
were not available to us for individual trials. We carried out a
sensitivity analysis of complications by excluding the unpublished
trials included in theKaiser review, criticised byHayashi (Feedback
1).
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
In this updated search we retrieved a total of 399 records in
the search for effectiveness studies, and a total of 1793 records
in the search for adverse effects studies. We excluded 18 safety
and 10 effectiveness studies (six were identified through both
search strategies as they assessed both dimensions). We identified
four prophylaxis, 12 treatment and four post-exposure prophy-
laxis (PEP) trials. Twenty-eight studies were retrieved and 29 stud-
ied were excluded, Figure 1 and Figure 2. However, two studies
provided information on harms of oseltamivir (Blumentals 2007;
Toovey 2008). This left 20 included trials in 19 publications (Aoki
2000; Boivin 2000;Hayden1997;Hayden1999a;Hayden2000a;
Hayden 2004; Kaiser 2000; Kashiwagi 2000a; Kashiwagi 2000b;
Li 2003; Makela 2000; Matsumoto 1999; MIST 1998; Monto
1999a; Monto 1999b; Monto 2002; Nicholson 2000; Puhakka
2003; Treanor 2000; Welliver 2001).
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Figure 1. Flow of studies identified from randomised controlled trials.
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Figure 2. Flow of studies identified from the search for evidence from post-marketing studies (excluding
AERS)
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Included studies
Prophylaxis trials
We identified four prophylaxis trials, two comparing a total of
697 treated with inhaled zanamivir 10 mg daily versus 602 with
placebo (followed for 22 days) (Kaiser 2000; Monto 1999a), and
two trials comparing a total of 675 treated with oral oseltamivir
75 mg daily versus 413 placebos (followed for 49 days) (Hayden
1999a; Kashiwagi 2000a). Compared to placebo,NIs had no effect
against ILI (RR 1.28, 95% CI 0.45 to 3.66 for oseltamivir 75 mg
daily, RR 0.76, 95% CI 0.49 to 1.19 for zanamivir 10 mg daily)
(Figure 3). Higher dosages made no difference, although this is
based on a single study with only nine events (Hayden 1999a;
Hayden 2000a; Kaiser 2000;) Oseltamivir 75 mg daily reduced
the chance of symptomatic laboratory-confirmed influenza (RR
0.24, 95% CI 0.12 to 0.48). Zanamivir 10 mg daily was simi-
larly efficacious (RR 0.33, 95% CI 0.18 to 0.59) (Figure 4). Nei-
ther protected against asymptomatic influenza (Hayden 1999a;
Kashiwagi 2000a; Monto 1999a).
Figure 3. Forest plot of comparison: 1 NI versus placebo for prophylaxis, outcome: 1.1 Influenza-like illness.
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Figure 4. Forest plot of comparison: 1 NI versus placebo for prophylaxis, outcome: 1.2 Influenza
(symptomatic).
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Treatment trials
We identified eight treatment trials of zanamivir (Aoki 2000;
Boivin 2000; Hayden 1997; Makela 2000; Matsumoto 1999;
MIST 1998; Monto 1999b; Puhakka 2003), of which two (Aoki
2000; Boivin 2000) were linked to others (MIST 1998; Monto
1999b) (a total of 1878 in the treatment arm and 1310 controls,
with a mean length of follow up of 26 days). Four of oseltamivir
(Kashiwagi 2000b; Li 2001; Nicholson 2000; Treanor 2000), and
another trial (Li 2003) was linked to a redundant publication (Li
2001), (totaling 1118 treatment; 679 controls, 21 days follow up).
There was evidence of benefit in shortening duration of influenza
like-illness for zanamivir (hazard ratio, (HR) 1.24, 95% CI 1.13
to 1.36), and for oseltamivir (HR 1.20, 95% CI 1.06 to 1.35),
(Figure 5). This finding is likely to be due to the high percentage of
influenza-like illness caused by influenza in some of the included
trials (for example, 66%) (Nicholson 2000).
Figure 5. Forest plot of comparison: 2 NI versus placebo for treatment, outcome: 2.1 Time to alleviation of
symptoms (ITT).
Post-exposure prophylaxis (PEP) trials
We identified twoPEP trials of different design assessing the effects
of oseltamivir. Hayden 2004 is a C-RCT comparing the effects
on household contacts of expectant treatment with oseltamivir
with commencing immediate PEP. Welliver 2001 investigated the
effects of oseltamivir on the spread of influenza by randomising
household contacts of index cases with influenza to the active
principle or placebo. The mean and median oseltamivir arm size
was 447 (25th percentile 422 and the 75th% percentile 470).
Two further PEP trials assessed zanamivir (Hayden 2000a; Monto
1999a). In both trials, household contacts of an index case with ILI
were randomised to either placebo of zanamivir. The oseltamivir
trials reported significant protection for household (RR 0.16 and
0.42) and the zanamivir trials reported similar results (RR 0.19
and 0.21).
See the ’Characteristics of included studies’ table for a full descrip-
tion of all included studies.
Excluded studies
For this 2009 update overall, 29 studies made up of 10 effective-
ness and 10 safety studies (six were identified by both searches)
were excluded. After additional deliberations, another three ef-
fectiveness studies were excluded (Blumentals 2007; Kaiser 2003;
Toovey 2008). This left 20 included trials in 19 publications. Two
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studies that were excluded from the effectiveness screen were in-
cluded in the safety data sources (Blumentals 2007; Toovey 2008),
Figure 1 and Figure 2.
Risk of bias in included studies
One prophylaxis trial had adequate methodological quality (
Monto 1999a), one had an unclear measures to protect dou-
ble blinding (Hayden 1999a) and two (Kaiser 2000; Kashiwagi
2000a) had unclearly described methods. Kaiser 2000 reported
no dropouts from the trial. Four treatment studies (Makela
2000; MIST 1998; Nicholson 2000; Treanor 2000) had adequate
methodological quality, three trials (Aoki 2000; Boivin 2000;
Kashiwagi 2000b) has unclearly described processes, although two
(Aoki 2000; Boivin 2000) were linked to larger studies. The re-
mainder had at least one unclearly described item. One trial (Li
2003) did not include withdrawals in the analysis.
Withdrawals were included in all PEP trials but all other items
were poorly described. Hayden 2004 was an open-label C-RCT.
Allocation concealment was not described in the zanamivir trials.
Allocation
On the basis of the published text only five trials were judged
adequate by usual Cochrane Collaboration methods (Higgins
2008b). One trial on prophylaxis (Monto 1999a) and four on
treatment (Makela 2000; MIST 1998; Nicholson 2000; Treanor
2000).
Incomplete outcome data
Most of the trials were at risk of bias, arising frompoor descriptions
of the methods (Aoki 2000; Boivin 2000; Kaiser 2000; Kashiwagi
2000a; Kashiwagi 2000b; Hayden 1999a) such as no description
of losses to follow up and blinding (Kaiser 2000). Attempts to
deal with these shortcomings were unsuccessful. To address the
Hayshi comment (Feedback 1) we wrote to all first or correspond-
ing trial authors of studies on oseltamivir treatment. Although five
responded to our contact, none had original data and referred us to
the manufacturer (Roche), which was not able to unconditionally
provide the information as quickly as we needed it to update this
review (Doshi 2009). The Kaiser et al 2003 meta-analysis (Kaiser
2003) was made up of data from 10 studies. We were obliged to
exclude the meta-analysis because we were unable to determine
the number of healthy adults experiencing complications in each
study (some studies contained mixed populations of healthy and
comorbid participants), nor the number of patients experiencing
one of more of “bronchitis, lower respiratory tract infection, or
pneumonia” presenting to each study.
Other potential sources of bias
We are unable to assess the size and direction of the obvious bias
in the treatment data set due to the non-publication or partial-
publication of eight trials, as the data provided to us by Roche are
insufficient to fill the gaps in our understanding of the population,
methods and results of the studies.
Effects of interventions
We carried out three main comparisons with placebo: NIs in a pre-
exposure, post-exposure prophylaxis (PEP) and treatment roles.
We further subdivided each comparison according to outcome
case definition. We did not meta-analyse data from the PEP trials,
as they had different study designs.
Prophylaxis trials
Compared to placebo, NIs have no effect against ILI (RR 1.28,
95% CI 0.45 to 3.66 for oral oseltamivir 75 mg daily (Figure 3);
and RR 0.76, 95% CI 0.49 to 1.19 for inhaled zanamivir 10 mg
daily). Higher dosages appear to make no difference, although this
observation is based on single studieswith very lowviral circulation
(Hayden 1999a; Kaiser 2000).
The efficacy of oral oseltamivir 75 mg daily against symptomatic
influenza is 76% (RR 0.24, 95% CI 0.12 to 0.48), or 73% (RR
0.27, 95% CI 0.11 to 0.67) at 150 mg daily, although this last
observation is based on a single study. Inhaled zanamivir 10 mg
daily is 67% efficacious (RR 0.33, 95% CI 0.18 to 0.59) (Figure
4). The addition of an intranasal dose does not seem to enhance its
prophylactic activity (RR 0.66, 95% CI 0.17 to 2.53), although
again this last observation is based on a single study.
Oseltamivir confers 64% protection against symptomatic and
asymptomatic influenza (RR0.46, 95%CI 0.31 to 0.68) at a lower
dose of 75 mg daily. An increase to 150 mg daily does not appear
to enhance its activity (RR 0.48, 95% CI 0.29 to 0.80) although
this observation is based on a single study. Similarly zanamivir has
a 43% protective effect (RR 0.67, 95%CI 0.50 to 0.91) and based
on a single study the addition of intranasal dose does not appear
to enhance its activity (RR 0.77, 95% CI 0.38 to 1.56).
However, when the outcome is asymptomatic influenza no NI
has significant effects (oseltamivir 75 mg daily RR 0.73, 95%
CI 0.43 to 1.26; oseltamivir 150 mg daily RR 0.67, 95% CI
0.35 to 1.28; zanamivir 10 mg daily 0.98, 95% CI 0.65 to 1.47).
These observations are based on three studies (Hayden 1999a;
Kashiwagi 2000a; Monto 1999a) with a combined denominator
of 2974 in the presence of relatively high viral circulation (5% in
the combined placebo arms).
Oseltamivir induces nausea (OR 1.79, 95% CI 1.10 to 2.93),
especially at the higher prophylactic dose of 150 mg daily (OR
2.29, 95% CI 1.34 to 3.92).
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Post-exposure prophylaxis (PEP) trials
Hayden 2004 reports that PEP provided an efficacy of 58.5%
(15.6% to 79.6%) for households and of 68% (34.9% to 84.2%)
for individual contacts. Given the high circulation of virus (184
out of 298 index cases had influenza, 66% of which had influenza
AH1N1 and remainder influenza B virus) effectiveness was high
62.7% (26% to 81%).
Welliver 2001 reports 89% (67% to 97%) protective efficacy in
contacts of index cases with influenza and 84% (45% to 95%) for
index cases.
Neither trial reported the onset of viral resistance after five (Hayden
2004) and seven days (Welliver 2001) of prophylaxis at a dose of
75 mg twice daily (Hayden 2004) and once daily (Welliver 2001).
Neither the background rate of infection in the community nor
the viral strains are reported, although influenza A and B were co-
circulating at the time.
Monto 2002 reports a 79%effectiveness and 81%efficacy (64% to
90%) for households and82%for individuals against symptomatic
influenza, 55% to 59% against all asymptomatic and symptomatic
influenza. Zanamivir shortened duration of illness by 1.5 days and
was well tolerated and no viral resistance was reported.
Hayden 2000a concludes that zanamivir was 79% (57% to 89%)
effective and 72% (42% to 87%) effective in preventing contacts
from developing symptomatic influenza and 53% (27% to 70%)
effective and 48% (15% to 68%) efficacious in preventing symp-
tomatic and asymptomatic influenza. Zanamivir also shortened
duration of symptoms by 2.5 days. There was no evidence of the
onset of resistance.
Treatment trials
Time to alleviation of symptoms (considering ITT population)
was assessed in nine trials (Hayden 1997; Li 2003; Makela 2000;
Matsumoto 1999; MIST 1998; Monto 1999b; Nicholson 2000;
Puhakka 2003; Treanor 2000). The estimated hazard ratios for
zanamivir were greater than one, hence in favour of the treated
group and there was no evidence of heterogeneity (I2 statistic =
0%). The pooled hazard ratio is 1.24 (95% CI 1.13 to 1.36)
indicating that the treated group are 24%more likely to have their
symptoms alleviated than the placebo group by a given time-point.
We obtained a similar result for oseltamivir (hazard ratio 1.20, 95%
CI 1.06 to 1.35) (Figure 5). For time to alleviation of symptoms in
influenza-positive participants, the hazard ratios were significantly
in favour of the treated group 1.33 (95% CI 1.29 to 1.37) for
zanamivir and 1.30 (95% CI 1.13 to 1.50) for oseltamivir. There
was no evidence of heterogeneity for the zanamivir data meta-
analysis, but I2 statistic was 37.5% for oseltamivir. Application
of the fixed-effect model did not materially alter the hazard ratio
(Boivin 2000; Hayden 1997; Kashiwagi 2000b; Li 2003; Makela
2000; Matsumoto 1999; MIST 1998; Monto 1999b; Nicholson
2000; Puhakka 2003; Treanor 2000).
Time to return to normal activities (considering ITT popula-
tion) was assessed by four studies (Matsumoto 1999; MIST 1998;
Monto 1999b; Treanor 2000). The pooled estimated hazard ra-
tios for zanamivir was 1.28 (95% CI 1.13 to 1.45), while the sin-
gle study assessing oseltamivir (Treanor 2000) had a non-signif-
icant hazard ratio (1.23, 95% CI 1.02 to 1.48). There was no
heterogeneity (I2 statistic = 0). In influenza-positive participants
the pooled hazard ratio was just below significance 1.17 (95% CI
1.00 to 1.37, P value 0.06) for zanamivir (Makela 2000; MIST
1998; Hayden 1997) and significant for oseltamivir 1.34 (95%
CI 1.07 to 1.67) although this observation is based on a single
study (Treanor 2000). There was no evidence of heterogeneity (I
2 statistic = 0%).
Five studies reported assessing the effect of NI administration on
viral load (as estimated by mean nasal titres of excreted viruses at
24 and 48 hours since randomisation) (Boivin 2000; Kashiwagi
2000b; Nicholson 2000; Puhakka 2003; Treanor 2000). Titres
were significantly diminished by both zanamivir and oseltamivir
(WMD -0.62, 95% CI -0.82 to -0.41). The effect is more marked
the longer the time since randomisation (and commencement
of treatment). Exclusion of data from the Treanor 2000 and
Nicholson 2000 studies does not affect our conclusions. There was
evidence of heterogeneity (I2 statistic = 34.6%) but analysis using
a fixed-effect model did not materially affect our findings, except
for the comparison zanamivir against placebo where the effect on
mean nasal titres at 48 hours since randomisation is not significant
when analysed using a fixed-effect model. However, treatment did
not suppress viral excretion, apparently regardless of the dose. We
found insufficient data to comment on the effects on nasal excre-
tion of viruses of higher doses of medication.
There is insufficient evidence for oseltamivir 75 mg daily in pre-
venting complications (pneumonia, bronchitis, otitis media, si-
nusitis) requiring antibiotics in influenza cases (RR 0.57, 95% CI
0.23 to 1.37) (Figure 6). There is also insufficient evidence for
zanamivir in preventing complications of all types in influenza
cases (RR 0.73, 95% CI 0.50 to 1.06). However, zanamivir is ef-
fective in preventing complications of all types in the ITT popula-
tion (RR 0.69, 95% CI 0.49 to 0.96), although these observations
are based on a single study (Makela 2000).
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Figure 6. Forest plot of comparison: 2 NI versus placebo for treatment, outcome: 2.6 Complications - all
types (influenza cases only).
Oseltamivir is associated with nausea (OR 2.50, 95% CI 1.49 to
4.20). Finally, use of relief medications and antibiotics is unaf-
fected by consumption of NIs (OR 0.82, 95% CI 0.60 to 1.11).
Evidence of harms
The trials identified only one serious adverse event (Nicholson
2000) (so labelled in the Japanese data, a patientwith neutropenia),
and, in particular, noneuropsychiatric events.Oseltamivir induced
nausea (OR 1.79, 95% CI 1.10 to 2.93), especially at the higher
dose of 150 mg daily (OR 2.29, 95% CI 1.34 to 3.92) (Figure 7).
No statistically significant adverse event was found for zanamivir
from the trials (Matsumoto 1999; MIST 1998; Monto 1999b;
Puhakka 2003).
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Figure 7. Forest plot of comparison: 1 NI versus placebo for prophylaxis, outcome: 1.5 Adverse events -
nausea.
Two published studies reported additional retrospective compar-
ative safety data on oseltamivir (Blumentals 2007; Toovey 2008).
Their data suggest an incidence of neuropsychiatric adverse events
per 1000 adults aged between 18 to 49 at 14 days and 30 to 40
at 30 days (Blumentals 2007) and for neuropsychiatric adverse
events in prospective clinical trials, an incidence of 0.5% (Toovey
2008).
AERS-1includes 2275 adverse event reports for oseltamivir and
453 for zanamivir (excluding follow up reports on the same indi-
vidual event) generated worldwide between December 1999 and
July 2009 (the month our request was answered). Unfortunately
it indicates neither reporting country nor how long the event oc-
curred before receipt of the report by the FDA. The period from
2004 onwards overlaps with AERS-2, which has reports from Jan-
uary 2004 to March 2009, indicating both initial and follow up
reports, and reporting the date of the adverse event (FDA 2009b;
FDA 2009c). From July 2005 it indicates the reporting country.
From July 2005 to March 2009, 1205 initial adverse events oc-
curred. Most (681, 56.5%) were reported from Japan, followed
by the United States (390, 32.4%). Most (1109, 92.0%) were for
oseltamivir (perhaps reflecting its higher use). A disproportionate
amount of reports are for people aged less than 20 (with data on
age missing for many).
D I S C U S S I O N
Summary of main results
Role of NIs in seasonal influenza
We have assembled a good-quality up to date evidence base of
the prophylactic and treatment effects of NIs. These compounds
have low effectiveness, high efficacy and appear to be well toler-
ated, with the possible exception of oseltamivir-induced nausea
and vomiting and zanamivir-induced diarrhoea. Existing trials on
NIswere clearly designed and undertakenwithin a registration and
regulation perspective. This is reflected in the cryptic reporting of
continuous outcome data which forced us to resort to summary
measures such as hazard ratio (HR), which although methodolog-
ically virtuous, may not be relevant to workers in the field. Onset
of resistance is a possibility.
Although none of the studies included in the review reported it,
Kiso and colleagues found an 18% isolation rate of NI-resistant
A/H3N2 viruses in 50 very young children at day 4 of treatment,
and a high prolonged viral excretion even after five days of treat-
ment (Kiso 2004). Resistance to oseltamivir is reported to be the
around 0.5% from other trials in the Roche database (Ward 2005).
Recently resistance of H1N1 viruses to oseltamivir has been re-
ported from 59/437 (14%) isolates from nine European countries
(Lackenby 2008). Given the highly selective nature of the isolates
it is not possible to generalise the data. However the onset of resis-
tance is a further reason against the routine use of neuraminidase
inhibitors.
NIs affect influenza symptoms, either preventing their appearance
or curtailing their duration and, although we found clear evidence
of their capacity to interrupt transmission of seasonal influenza in
households, NIs do not prevent infection and decrease - but do not
interrupt - nasal shedding of seasonal influenza viruses. We cannot
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explain how NIs can affect respiratory complications of seasonal
influenza such as bronchitis and pneumonia while not preventing
infection and this effect should be further studied. An explana-
tion for what we have observed is a possible effect in preventing a
proportion of NI recipients to seroconvert into symptomatic in-
fluenza cases. This would explain the observed effects of NIs on
serious complications and interruption of transmission in house-
holds during seasonal influenza. Whichever explanation is cho-
sen, prophylactic use of NIs in a serious epidemic or a pandemic
may enhance vulnerability to infection by preventing seroconver-
sion and facilitating the selection of NI-resistant mutant viruses.
Because of their low effectiveness and the possibility of the onset
of resistance we conclude that NIs should not be routinely used
in seasonal influenza. In the case of a serious localised confirmed
epidemic, NIs could be used to prevent serious complications.
Our inability to provide a satisfactory response to the observations
made in the Hayashi challenge, compounded by the inability of
corresponding authors or the manufacturers to provide their orig-
inal data, (for the latter, because it was contingent on our signing a
secret confidentiality agreement), has undermined our confidence
in our previous findings Cooper 2003. The treatment effects of
oseltamivir now seem less credible.
NIs had low effectiveness, high efficacy against symptoms (short-
ening the illness by half to one day, and preventing symptoms
from appearing), and initially appeared to be well tolerated (with
the possible exception of oseltamivir-induced nausea and vomit-
ing and zanamivir-induced diarrhoea).
Commercial interests may explain the cryptic reporting of contin-
uous outcome data which forced us to resort to summary measures
such as hazard ratio (HR). A surprising finding is the very high
percentage (from 57% to 78%) of influenza in the ITT popula-
tions of the neuraminidase treatment trials. We remain at a loss to
explain this (Jefferson 2009a) and questions to authors and phar-
maceutical company remain unanswered or unsatisfactory, (We-
bExtra).
Viral resistance ismonitored by several organisations.One recently
reported resistance of seasonal A/H1N1 to oseltamivir at 98%
of 259 tested specimens, but no resistance for the 26 novel A/
H1N1 tested, or for any of 285 specimens to zanamivir (ECDPC
2009). Yet resistance was reported as 0.5% from other trials in the
Roche database (Ward 2005). The risk of resistance is one reason
to advise against routine use of neuraminidase inhibitors except in
life-threatening situations.
Role of NIs in avian influenza
We identified no comparative evidence of the role of NIs in avian
A/H5N1 influenza or for the current novel A/H1N1 pandemic.
Oseltamivir was used against three subtypes of avian influenza
viruses with proven bird-to-human and human-to-human trans-
mission: A/H5N1, A/H7N7 and H7N3. The virological and
transmission profile of avian H5N1 influenza is not clear. One
review reports that experience from the cases of avian influenza
transmitted to man in South East Asia suggests that viral shedding
commences before symptoms appear and ceases after 48 hours
from onset of symptoms (Yuen 2005). The WHO-led review of
H5N1 influenza cases suggests that viral shedding and infectiv-
ity of index cases could be protracted (WHOWC 2005). What
appears clear however, is that viral load can be up to 10 times
greater than in seasonal influenza (WHOWC 2005). In the South
East Asia outbreaks, use of oseltamivir was not associated with
any obvious effect on mortality, although this could be due to late
commencement of therapy and high initial viral load. Resistance
to oseltamivir was detected in up 16% of children given the drug
(WHOWC 2005), accordingly with evidence from Japan (Kiso
2004), a country with very high NI prescription rates, and in two
out of eight Vietnamese people aged eight to 35 years (de Jong
2005).
The apparently common feature favouring the selection of resis-
tant viruses is immunological naivety to the infecting viral subtype.
A large outbreak of avian A/H7N7 influenza with bird-to-human
and human-to-human transmission took place in chicken farms
in the Netherlands between February and June 2003. Eighty-five
of the 453 people who reported symptoms (mainly ILI and/or
conjunctivitis) had A/H7N7 isolation from lacrimal fluid and/or
upper airway swabs. Among other measures, PEP with oseltamivir
75 mg was started. Ninety people in the case registry probably
had prophylactic treatment. Avian influenza virus infection was
detected in one of 38 (2.6%) people who used oseltamivir, com-
pared with five of 52 (9.6 %) who reported that they had not
taken prophylactic medication. The difference was not significant
(P value 0.38), probably because of small numbers and of the late
nature of the commencement of PEP (Koopmans 2004). A similar
outbreak of A/H7N3 took place in British Columbia, Canada in
2004. Twelve possible cases (22% of total) reported taking pro-
phylactic oseltamivir at symptom onset, and 11 (20%) received
oseltamivir for treatment. Maximum duration of oseltamivir as-
sumption is thought to have been 12 weeks (Ward 2005). The
remaining 22 patients with suspected cases were identified more
than 48 hours after onset or refused treatment. All recovered fully
(Tweed 2004). Evaluation of the effects of oseltamivir was outside
a formal study and in all three cases data on the effectiveness of
oseltamivir are insufficient to reach a conclusion. The use of NIs
in avian influenza or in a possible pandemic is not supported by
any credible data at present and we have doubts as to the generalis-
ability of the evidence from seasonal influenza to avian influenza.
Given the circumstances (ad hoc studies carried out during actual
localised epidemics of avian influenza and the future characteris-
tics of any pandemic) this is not surprising.
It should be remembered that at times the manufacturer makes
no claims for oseltamivir to influence symptoms and complica-
tions: “Tamiflu has not been proven to have a positive impact
on the potential consequences (such as hospitalisations, mortality,
or economic impact) of seasonal, avian, or pandemic influenza”
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(Doerler 2009). Since NIs do not prevent infection or stop nasal
viral excretion, they may be a sub-optimal means of interrupting
viral spread in a pandemic. If used to contain a severe pandemic
outbreak, NIs should be part of a package of measures to interrupt
spread, including physical measures (Jefferson 2009d), rather than
used alone. Finally, the inability of NIs to prevent infection and
to suppress viral nasal excretion raises doubts as to their effective-
ness in interrupting viral spread in a pandemic, although NIs may
have a role in addressing symptoms and complications. We con-
clude that in a pandemic, NIs should be used within a package of
measures to interrupt spread, that is to say, together with barrier,
distance and personal hygiene measures.
Possible rare harms associated with NIs
A key limitation of the post-marketing pharmaco-vigilance data
we obtained from FDA is the likely under-representation of non-
USA-generated reports. Manufacturers are not required to inform
FDA of non-USA events that are not “both serious and unex-
pected” (FDA 2009a). This has important implications for eval-
uating the complete safety profile of oseltamivir, as 79% of global
consumption has occurred outside of the USA (76% in Japan)
(Toovey 2008). Of particular concern are neuropsychiatric adverse
events (NPAEs) known to the manufacturer but not in the AERS
database. The Roche Global Safety Database contains reports of
2466 NPAE patients between 1999 and 15 September 2007 of
which they classified 562 (23%) as “serious” (Toovey 2008). How-
ever, the total AERS database (all types of adverse events) during
this time period contains only 1805 reports.
Another important limitation of the AERS database is the FDA’s
practice of not registering intoAERS non-electronically submitted
reports of non-serious adverse events three years after a drug’s initial
approval (personal correspondence with FDA 14 October 2009).
There is a possible association with NIs and the onset of rare
harms. According to a review of phase IV evidence from eight cases
(adolescents and adults) by Hama (Hama 2008), oseltamivir may
induce sudden behavioural changes in recipients including hallu-
cination and suicidal tendencies and sudden death while sleeping.
This evidence comes hard on the heels of the review ordered by
the Japanese government which is in part triggered by the 567
serious neuropathic cases received since the 2001 launch of the
drug and May 2007 (Hama 2008). However it is estimated that >
36 million doses have been prescribed since 2001 (Toovey 2008),
making such harms (even if confirmed) rare. These findings are
similar to our review of the US AERS data (Jefferson 2009b). We
therefore found under-reported evidence of varied quality which
could not answer concerns about the toxicity of NIs, especially
oseltamivir. Governments should set up studies to monitor the
safety of oseltamivir (Jefferson 2009b).
In the course of conducting this review it was discovered that
Chugai Pharmaceuticals Co., Ltd. a Japanese subsidiary drugman-
ufacturer controlled by Hoffmann La Roche Ltd. had published
adverse event data from randomised trials of oseltamivir on its web
site. Data from prophylaxis trials comes from Hayden 1999a as
well as two trials in the elderly (one unpublished). Notable adverse
events are presented in Table 1 where there is strong evidence of
increased incidence of nausea and vomiting due to oseltamivir as
well as some evidence of an increased incidence of headache, pain
in extremities, earache, major psychotic events, hyperglycaemia,
and renal/urinary tract adverse events. Data from treatment trials
comes fromNicholson 2000 and Treanor 2000, as well as from an
unpublished study of otherwise healthy adults. These data, shown
in Table 2, show strong evidence of increased incidence of nausea
and vomiting due to oseltamivir.
Table 1. Adverse events in randomised controlled trials of oseltamivir for prophylaxis (75 mg o.d. group of WV15673/697,
WV15708 and WV15825#)
Type of event (during on-treat-
ment unless indicated as “+off”)
*a
Placebo
(n = 973)
n (%)
Oseltamivir 75mg o.d.
(n = 986)
n (%)
P-value
(Fishers exact)
All AEs 1780 1933
Patients with any AE 673 (69.2) 717 (72.7) 0.091
Nausea 50 (5.1) 92 (9.3) < 0.001
Vomiting 9 (0.9) 27 (2.7) 0.004
Diarrhoea 38 (3.9) 49 (5.0) 0.27
All GI tract 155 (15.9) 214 (21.7) 0.001
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Table 1. Adverse events in randomised controlled trials of oseltamivir for prophylaxis (75 mg o.d. group of WV15673/697,
WV15708 and WV15825#) (Continued)
Headache 243 (25.0) 286 (29.0) 0.047
All neurological 270 (27.7) 314 (31.8) 0.048
Pain in extremities 5 (0.5) 16 (1.6) 0.026
Eearache 2 (0.2) 11 (1.1) 0.022
Aall ear and vestibular 8 (0.8) 22 (2.2) 0.015
Major psychotic *b 0 (0.0) 5 (0.5) 0.062
Major psychotic +off *c 1 (0.1) 8 (0.8) 0.039
+Major psychiatric *d 7 (0.7) 17 (1.7) 0.062
All psychiatric 13 (1.3) 24 (2.4) 0.096
All psychiatric +off 18 (1.8) 31 (3.1) 0.082
Mild psychiatric *e 6 (0.6) 9 (0.9) 0.61
Hyperglycaemia +off *f 0 (0.0) 8 (0.8) 0.008
Renal/urinary tract *g 3 (0.3) 15 (1.5) 0.007
Upper respiratory infection 51 (5.2) 57 (5.8) 0.62
Influenza 41 (4.2) 46 (4.7) 0.66
Influenza like illness 23 (2.4) 19 (1.9) 0.54
Fever (general system) 33 (3.4) 28 (2.8) 0.52
Viral infection 5 (0.5) 4 (0.4) 0.75
All infections 227 (23.3) 234 (23.7) 0.87
*a?“+off”: including events during off-treatment period.
*b: major psychotic disorders?hallucination, Korsakov psychosis, schizophrenia, psychosis NOS, attempted suicide?
*c: one psychosis NOS in placebo group and hostility, hallucination aggravated and delusion in Tamiflu group were added.
*d?*a+b+major psychiatric events(depression, depression worsened, intrinsic depression, confusion, bipolar mood disorders).
*e?mild psychiatric events: all others that are not included in *a,*b,*c and *d? anxiety, alcoholism, sleep disorder, stress symptoms,
restlessness are included.
*f? 4 hyperglycaemia and 3 diabetes aggravated during on-treatment, and one diabetes aggravated during off-treatment period.
*g? one nephrotic syndrome and one acute renal failure in Tamiflu group.
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#Sources: Chugai Pharm Co 2004. New drug approval package (NAP) of oseltamivir (in Japanese); oseltamivir capsule for prevention
(2004) (in Japanese): available at: http://www.info.pmda.go.jp/shinyaku/g040703/index.html?submit3=%C9%BD%BC%A8
Hama R. Re: Oseltamivir: psychotic and neurological adverse reactions in the randomized controlled trials Rapid response: http://
www.bmj.com/cgi/eletters/339/dec07˙2/b5106#227187
Table 2. Comparison of adverse events in healthy adults (< 65 years) in oseltamivir treatment trials
(WV15670,WV15671,WV15730)*
Type of event Placebo (n = 466)
n (%)
75mg b.i.d. (n = 479)
n (%)
P-value
(Fishers exact)
Vomiting 15 (3.2) 57 (11.9) <0.001
Nausea 29 (6.2) 70 (14.6) <0.001
Insomnia 3 (0.6) 7 (1.5) 0.34
Constipation 1 (0.2) 4 (0.8) 0.37
Back pain 2 (0.4) 4 (0.8) 0.69
Type of dizziness 2 (0.4) 4 (0.8) 0.69
Headache 11 (2.4) 13 (2.7) 0.84
Pharyngitis 5 (1.1) 6 (1.3) 1.0
Stomach ache 11 (2.4) 12 (2.5) 1.0
Fatigue 7 (1.5) 6 (1.3) 0.79
Herpes simplex 5 (1.1) 4 (0.8) 0.75
Fever 4 (0.9) 2 (0.4) 0.45
Cough 10 (2.1) 7 (1.5) 0.47
Dizziness 16 (3.4) 11 (2.3) 0.33
Nasal congestion 10 (2.1) 5 (1.0) 0.20
Diarrhoea 40 (8.6) 35 (7.3) 0.47
*Source: PMDA website document, Tamiflu 75 mg, Chugai document, p.294
Overall completeness and applicability of
evidence
Wehave concerns about the difference between efficacy (treatment
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response to influenza virus infection) and effectiveness (the real-
life response to influenza-like illness, when real cases of influenza
are indistinguishable from other causative agents not responsive
to neuraminidase inhibitors) (Smith 2006). Understanding the
proportion of influenza-like illness caused by both seasonal and
epidemic influenza is critical to generalising the results of this
review to clinical practice. The finding of treatment effectiveness
for the neuraminidase inhibitors may be enhanced by the high
percentage of influenza-like illness caused by influenza in some of
the included trials -for example, up to 80% (Kashiwagi 2000b).
Quality of the evidence
Only five trials were judged adequate by usual Cochrane Collabo-
rationmethods (Higgins 2008b): one prophylaxis (Monto 1999a),
and four treatment trials (Makela 2000; MIST 1998; Nicholson
2000; Treanor 2000). There was risk of bias in most trials, aris-
ing from poor descriptions of the methods (Aoki 2000; Boivin
2000;Kaiser 2000;Kaiser 2003;Hayden1999a;Kashiwagi 2000a;
Kashiwagi 2000b), such as no description of loss of follow up and
blinding (Kaiser 2000). Attempts to address shortcomings were
unsuccessful: although four out of five first authors of oseltamivir
trials responded to our contact, none had original data and referred
us to the manufacturer (Roche).
Data about the effectiveness against influenza complications con-
fused us. After studying available FDA and EMEA regulatory
product information documents, we asked the EMEA for the ba-
sis behind its decision to approve statements that oseltamivir re-
duces lower respiratory tract complications (EMEA 2009). An-
swers did not resolve this satisfactorily. We contacted the manu-
facturer (Roche), asking for the complete complications data, in
particular the unpublished data used by Kaiser et al (Kaiser 2003)
as indicated in the Hayashi Feedback comment. In response, the
lead review author was sent a confidentiality agreement which
included a clause forbidding ever mentioning the confidentiality
agreement’s very existence (WebExtra).We felt signingmight com-
promise our aims.WepersistedwithRoche,whoprovided excerpts
from company study reports apparently authored by people who
did not appear in the published trials, and with insufficient detail
to understand some data (for example, complication data from
several trials were combined). This precluded us from addressing
the Hayashi Feedback comment. It also meant we were obliged
to now disregard a Roche-funded review of 10 trials containing a
mixture of published and unpublished data (Kaiser 2003) that is
being promoted by the manufacturer (Burns 2009) and cited in
US influenza treatment recommendations (Burns 2009).
Potential biases in the review process
In our 2005 review (Jefferson 2006) we failed to resolve the ques-
tions posed by Hayashi, the numerous inconsistencies found dur-
ing the review process (Doshi 2009) and to assess the harms pro-
file of oseltamivir in a satisfactory manner. This in our view, may
present an uncertain but perhaps optimistic view of the perfor-
mance of oseltamivir.
Agreements and disagreements with other
studies or reviews
Our review is now in disagreement with the conclusions of the
Burch 2009, Tappenden 2009, and Turner 2003 reviews as our
investigations could not answer the Hayashi comment and we
were forced to exclude the Kaiser et al 2003 (Kaiser 2003) data on
the effects of oseltamivir on complications
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We do not recommend NIs for routine use in seasonal influenza
except for life-threatening illness, and in circumstances where they
used as an adjunct to other public health measures. We urge cau-
tion in the administration of NIs until some of the problems such
as psychotropic effects and resistance have been clarified.Updating
this Cochrane review has increased uncertainty about the safety
of NIs, their capacity to interrupt viral transmission, or to affect
complications rates.
Implications for research
To provide that, adequate trials should be carried out to test NIs
against a viable alternative for symptoms and duration of illness
(such as a non-steroidal anti-inflammatory drug, or a statin) (Frost
2007), and compare its performance against hand washing and
masks to interrupt influenza transmission (Jefferson 2009d), and
powered to detect potentially rare adverse events.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Aoki 2000
Methods Multicentre, randomised, double-blind parallel group study, performed in 14 countries in Europe and
North America during the 1995 - 1996 winter.
Participants One thousand two hundred and fifty six patients were included in study, of which 722 had laboratory
confirmed influenza. The report only includes data for the 722 influenza cases. Participants were healthy
individuals over 13 years old with acute influenza like illness (ILI) lasting less than 48 hours. The patients
had to be able to use the inhaler and nasal devices. Patients with unstable chronic illness (for example,
hospitalised) or were pregnant or breast feeding were excluded. Randomisation was carried out with an
allocation schedule of 2:2:1:1 respectively
Interventions Treatment lasted for five days
Outcomes Serological:
Serum samples were collected on days 1 and 21, and assayed for the presence of anti-influenza antibodies
by haemagglutination inhibition
Effectiveness:
ILI (feverishness and at least two of the following symptoms: headache, myalgia, cough, or sore throat).
Productivity
Health status
Sleep quality
Healthcare utilisation
Treatment satisfaction
Social functioning
Physical functioning
Role functioning
Body pain
Current health perception
Psychological distress
The clinical efficacy of zanamivir and was reported is the Monto 1999c trial
Safety outcomes are not reported
Notes The authors conclude that zanamivir treatment reduced absenteeism, improved patient productivity and
well being, and reduced the additional use of healthcare resources in patients with influenza. It is very
difficult to understand the basis for this conclusion when Table II shows equal proportion of influenza
cases throughout the arms. The use of aggregate measures such as lest-squares mean scores for health status
indicators and presentation in histogram form makes interpretation very difficult
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Boivin 2000
Methods Double-blind, randomised, placebo controlled, multi centre sub-study, part of the MIST study, assessing
the relationship between alleviation of all clinical important symptoms (as defined by no fever and other
flu symptoms recorded as absent or mild for at least 24 hours) and reduction of viral load. The study was
conducted during the 1997-1998 season in Québec and Winnipeg, Canada
Participants Thirty-five patients were enrolled. 27 (77%) had an influenza virus infection laboratory-confirmed on
day 1. All subjects had influenza A virus H3 infections. 10 received a placebo, 17 received zanamivir.
Three influenza virus positive high-risk subjects were enrolled (2 in the placebo, 1 in zanamivir group).
Healthy adolescents and adults, older than 12 years, and high risk subjects (defined as those with chronic
respiratory, cardiovascular, or renal disease) with naturally occurring influenza A virus infections
Interventions Inhaled zanamivir 10 mg 2 x daily for 5 days
Outcomes Laboratory:
serial swabs
viral resistance insurgence analysis
viral load
Effectiveness:
fever
time to alleviation of symptoms
Safety:
no safety outcomes are mentioned
Notes The authors conclude that: 1) zanamivir produced a rapid antiviral effect following inhalation, and this
was noted as early as 12 hours after beginning treatment, 2) the decrease in virus load induced by zanamivir
correlatedwith a significant reduction in themedian time to alleviation of symptoms. 3) neither phenotypic
nor genotypic assays detected any evidence of emergence of zanamivir-resistant strains during therapy.
This is a sub-study of the pivotal treatment trial MIST. The claim of the relation between decreased
viral load and alleviation of symptoms does not appear to be substantiated in the text of the report. All
outcomes reported are non-clinical
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Hayden 1997
Methods Two multi centre trials in North America (38 centres, 220 individuals) and Europe (32 centres, 197
individuals) conducted during the 1994-1995 influenza season. Both trials assessed the treatment effects
of zanamivir using a randomised, double-blind, placebo controlled design.
Participants Otherwise healthy individuals with symptoms suggestive of influenza persisting longer than 48 hours.
Mean ages of subjects in the three arms were 31 to 33 years
Interventions Participants were randomised to receive either 10 mg of inhaled zanamivir by mouth plus 6.4 mg by
intranasal spray or 10 mg of inhaled zanamivir and intranasal placebo spray or aqueous placebo by both
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Hayden 1997 (Continued)
routes twice daily for five days. During convalescence HAI titres were assessed and 262 individuals had
laboratory confirmed influenza. Of these, 56% were due to A/H3N2 and 44% to B virus
Outcomes Overall nine placebo patients and ten from each of the other arms withdrew or were lost to follow up
(explained in the text as failure to at tend for the follow up visits). The major outcome assessed in the trial
was “time to alleviation of major symptoms” (defined as absence of fever and headache, muscle ache, sore
throat and cough). Additionally, time to resumption of usual activities are also reported
Notes Individuals who commenced treatment 30 hours or less from the onset of illness fared significantly better
than those who commenced later. Both interventions significantly shortened duration of illness compared
to placebo (5.3 and 5.4 days compared to 6.3 days). Inhaled and intranasal zanamivir significantly short-
ened non-effective time compared to placebo. Importantly, no effect was seen on non-influenza infected
patients (although the data are not presented in the text). Adverse effects are presented in the text as overall
and broken down by generalised (respiratory tract and gastrointestinal) and local (perinasal). The authors
conclude that zanamivir is safe and effective treatment against influenza A and B if given early in the
illness.
Although clearly randomised, no details of allocation or double blinding are given. The intention to treat
analysis has clearly taken place
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Hayden 1999a
Methods Multicentre randomised double-blind placebo-controlled preventive phase III trials of oseltamivir. Follow
up was 8 weeks. Medication continued for 6 weeks after recognition of the outbreak in the study area.
Randomisation and allocation were carried by using a computer-generated sequence. Due to the low
incidence of influenza (2.4% or 38/1559) the data from the two studies were combined. The study was
conducted during the winter of 1997-1998 in Virginia, Texas and Kansas with circulating A/Sydney/5/
97 H3N2 strain
Participants One-thousand five-hundred and fifty-nine healthy unvaccinated adults aged 18 to 65. There were 33
withdrawals from the treatment arms and 21 from the placebo arm
Interventions Oral oseltamivir 75 mg daily (n = 520), or twice daily (n = 520) or placebo (n = 519) for six weeks.
Acetaminophen could also be taken by protocol agreement
Outcomes Serological/Laboratory:
viral isolation and paired sera for antibody titres were taken
Effectiveness:
influenza (presence of ILI symptoms and culture within two days of symptom onset and/or antibody rise)
asymptomatic influenza (antibody rise in the absence of symptoms)
ILI: oral temp of 37.2 degrees C or more with at least one respiratory (cough, sore throat, coryza) or one
constitutional symptom (aches, fatigue, headache, chills, sweats)
Safety: study withdrawals:
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Hayden 1999a (Continued)
withdrawals due to Aminotransferase concentration increase
withdrawals due to gastrointestinal events
headache
nausea
vomiting
Notes The authors conclude that protection of 76 per cent is satisfactory given the low level of influenza activity.
The study is reasonably reported but procedures for double blinding are not described and effectiveness
outcomes are very confusingly named and described
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Hayden 2000a
Methods Multicentre, double-blind, randomised, placebo-controlled PEP trial that took place during the 1998 to
1999 winter in the USA
Participants Two hundred and twenty one index cases aged 18 to 20 and 837 family contacts aged around 25 to 26
years in 337 families (168 assigned to placebo and 169 to zanamivir)
Interventions Index cases received either inhaled zanamivir 10mgs daily or placebo for five days. Family contacts received
either zanamivir 10 mgs daily or placebo for ten days
Outcomes Serological: serum assays, PCR and culture (with resistance assay)
Effectiveness: ILI
Efficacy: Influenza and duration of symptoms
Safety: not better defined but authors report a profile similar to placebo
Notes The authors conclude that zanamivir was 79% (57% to 89%) effective and 72% (42% to 87%) effective
in preventing contacts from developing symptomatic influenza and 53% (27% to 70%) effective and 48%
(15% to 68%) efficacious in symptomatic and asymptomatic influenza. Zanamivir shortened duration of
symptoms by 2.5 days. There was no evidence of the onset of resistance. Allocation concealment is not
described
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
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Hayden 2004
Methods (WV 16163)
Multicentre, open-cluster randomised trial conducted in Europe and North America during the 2000-
2001 influenza season. The aims of the study were to assess the effects of post-exposure prophylaxis (PEP)
with oseltamivir compared with standard treatment (oseltamivir if symptoms occurred in contacts) and
the possible onset of resistance.
Eligible households had a maximum of 3 and a minimum of 8 members, including at least 1 index case
and at least 2 eligible contacts aged 1 year or more. Children aged younger than 1 year were excluded.
Randomization was stratified by the presence or absence of an infant (aged younger than 1 year) in the
household and by the presence or absence of a second index case (IC) in the household.
ICs and contacts recorded symptoms twice daily on diary cards for 30 days
Participants Eight-hundred and twelve healthy and non-pregnant household contacts of 298 index cases presenting
with an influenza-like illness (temperature 37.8C or more plus cough and/or coryza) during a documented
community influenza outbreakwere randomised by household (n=277). Therewere 20 contact exclusions,
11 because of lack of information and 9 due to lack of laboratory infected status data
Interventions PEP with oseltamivir for 10 days or treatment at the time of developing illness (expectant treatment)
during the postexposure period beginning within 48 h of the reported onset of symptoms in the index case.
All index cases received oseltamivir treatment twice daily for 5 days. Contacts in the expectant treatment
arm were also given a standard 5-day treatment course if illness developed (adults and adolescents older
than 12 years received 75 mg oseltamivir capsules twice daily, whereas children aged 1 to 2, 3 to 5, and 6
to 12 years received 30, 45, and 60 mg oseltamivir suspension, respectively, twice daily). A second course
of treatment could be provided in the event that the subject developed an ILI after the completion of the
first course of oseltamivir
Outcomes Serological:
throat and nose swabs and paired serum samples for determining influenza strain-specific hemagglutina-
tion-inhibition (HAI) antibody titers
Effectiveness:
percentage of households with at least 1 secondary case of influenza during the 10-day period after the
start of treatment in the ICs (primary efficacy outcome)
Percentage of households with at least 1 secondary case of ILI during the 10-day period after the start of
treatment in the ICs
Both outcomes were also calculated for individual contacts and for children aged 1 to 12 years.
Duration of illness (time to alleviation of symptoms for treated ICs and for ill contacts: the first 24 h
period in which the severity of all influenza symptoms were remained as mild or none)
Efficacy analyses were carried out for:
intention-to-treat index-infected (ITTII) population defined as those households and contacts of labora-
tory-confirmed, influenza-infected ICs.
Subpopulation of contacts who were virus-negative at baseline (ITTIINAB)
Overall intention-to-treat (ITT) population (all randomised households and contacts, regardless of infec-
tion status in the IC).
Safety:
withdrawals
nausea
vomiting
The data for children aged 1 to 12 were not extracted
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Hayden 2004 (Continued)
Notes The authors conclude that oseltamivir is safe and effective in interrupting household transmission. A very
confusing report with unclear alternative interventions and outcomes which had to be pieced together
from fragments of text. Randomisation details are lacking together with cluster co-efficient data
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear D - Not used
Kaiser 2000
Methods Multicentre, double-blind, placebo-controlled randomised controlled trial. The trial assessed the pro-
phylactic activity of zanamivir after presumed exposure to influenza in the community. The study was
conducted from November 1995 to March 1996 in Europe and North America when A/H3N2 was the
predominant strain
Participants Five hundred and seventy five asymptomatic subjects aged 13 to 65 years (mean age 34 to 35 years) who
had been in close contact with index cases of influenza like illness of no longer than 4 days duration
(ILI was defined as temp of 37.8C or more or feverishness with at least two of the following: headache,
myalgia, cough and/or sore throat). No withdrawals are mentioned
Interventions Participants were randomised to four treatment groups:
1) 2 intranasal sprays of zanamivir (16 mg/mL) per nostril (0.1 mL per spray) plus 2 placebo inhalations
2) 2 zanamivir inhalations (5mg per inhalation) plus 2 placebo sprays per nostril
3) inhaled and intranasal zanamivir
4) 2 placebo inhalations and 2 placebo sprays per nostril
All were self administered for 5 days
Outcomes Serological/laboratory:
serum samples (days 1 and 21) and viral upper airways samples were taken
Effectiveness:
six point scale of influenza like symptoms ILI, including: -
headache
sore throat
feverishness, muscle aches, cough, nasal congestion, weakness
loss of appetite
Observations were recorded twice daily for 10 days
Safety:
no detailed outcome data are reported
Notes The authors conclude that short term treatment with intranasal zanamivir was ineffective. However,
inhaled zanamivir treatment reduced the rate of influenza, whichwas 2%to3%among zanamivir recipients
versus 6% among placebo recipients.
The results in the text are reported in a very confusing fashion. It is likely that “influenza at 21 days” and
“Symptomatic or asymptomatic influenza 21 days after initiation” are the same outcome reported twice
differently in the text and table 2. Because of the possibility of error, data on asymptomatic influenza have
not been extracted
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Kaiser 2000 (Continued)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Kashiwagi 2000a
Methods Double-blindplacebo-controlled randomised controlled trial of the preventive effects of oseltamivir against
influenza A and B. The study was carried out in 33 centres in Japan. Both H3N2 and H1N1 were co-
circulating at a low level the time with H3N2 accounting for 10 of the 13 cases in the placebo arm of the
trial. Follow up and administration of the drug was for 42 days, with a further post-administration of 57
days’ duration
Participants Three hundred and eight healthy subjects aged 16 to 89 (mean 34 years), predominantly non-smokers.
There were three withdrawals in the intervention arm (one each for adverse events, protocol violation and
voluntary withdrawal)
Interventions Oral oseltamivir (Roche) 75 mg or placebo daily for six weeks
Outcomes Serological:
viral antibody titres
Effectiveness:
Group 1: participants with fever of 37.5 degrees C or more and at least two other influenza symptoms
with laboratory confirmed influenza
Group 2: participants without fever of 37.5 degrees C or more or at least two other influenza symptoms
with laboratory confirmed influenza
Group 3: participants with no symptoms or signs with laboratory confirmed influenza
Group 4: participants with symptoms without laboratory confirmed influenza
Safety:
diarrhoea, abdominal pain upper, nausea, abdominal pain, vomiting, abdo. distension, stomatitis, loose
stools, retching, sore throat, faecal abnormality, gingivitis, constipation, oral discomfort, tooth loss, tooth
ache, gingival oedema, dyspepsia, food poisoning, oesophagitis, glossitis, enterocolitis, headache, sneezing,
dizziness, somnolence, insomnia, paraesthesia, cough, rhinorrhea, epistaxis, allergic rhinitis, nasal passage
irritation, nasal congestion, tonsillitis. Other adverse events are grouped by infectious, local, musculoskele-
tal, reproductive, metabolic, cutaneous, injury and poisoning, eye, vascular, ENT, renal.
An extensive list of laboratory and diagnostic tests is reported
Notes The authors conclude that oseltamivir is safe and effective in the prevention of influenza. Despite not
being able to consult the text, the tables and abstract report sufficient information. The study appears well
designed and well reported
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
32Neuraminidase inhibitors for preventing and treating influenza in healthy adults (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kashiwagi 2000b
Methods Double-blind placebo-controlled randomised trial of the treatment effects of oseltamivir against influenza
A and B. The study was carried out in 79 centres in Japan. Both H3N2 and H1N1 were co-circulating
at the time with H3N2 accounting for nearly 60% of infections in both arms of the trial. Follow up and
administration of the drug was for 5 days, with a further post-administration of 21 days’ duration
Participants Three hundred and sixteen subjects were enrolled, 162 in the placebo arm and 154 in the active arm
(including one in the placebo arm was given the study drug by mistake). There were 3 withdrawals from
the active arm (one each for overdosing not turning up for follow up and voluntary withdrawal) and
11 from the placebo arm (4 for adverse events, 4 for voluntary withdrawal, 1 was given the study drug
by mistake, 1 “other” and 1 for not turning up for follow up) so 151 in each arm completed the trial.
Participants were aged 16 to 89 (mean age 35.5 in the active arm and 33.6 in the placebo arm). Five were
inpatients. One hundred and twenty two participants were infected with influenza and 130 in the placebo
arm. These represented the ITTI population
Interventions Oral oseltamivir (Roche) 75mg or placebo twice daily for five days. In the ITTI population, administration
took place within 36 hours of onset of symptoms for all but 8 in the active arm and 5 in the placebo arm
Outcomes Serological:
viral antibody titres
Effectiveness:
time to resolution of illness (ITTI)
time to resolution of symptoms (ITTI)
cases of influenza (ITTI)
influenza viral titre
severity (symptom scores)
Safety:
diarrhoea, abdominal pain upper, nausea, abdominal pain, vomiting, abdo. distension, stomatitis, loose
stools, retching, sore throat, faecal abnormality, gingivitis, constipation, dry mouth, oral pain, tooth ache,
gingival oedema, dyspepsia, tongue coated, oesophagitis, glossitis, enterocolitis, headache, sneezing, dizzi-
ness, somnolence, insomnia, paraesthesia, cough, rhinorrhea, dizziness, grand mal convulsion, epistaxis,
allergic rhinitis, nasal passage irritation, nasal congestion, tonsillitis. Other adv events are grouped by
infectious, local, musculoskeletal, reproductive, metabolic, cutaneous, injury and poisoning, eye, cardiac,
ENT, renal.
An extensive list of laboratory and diagnostic tests is reported
Notes The authors concluded that oseltamivir is safe and effective in reducing length of illness. Lack of translation
of parts of the text make assessment of quality difficult. The imbalance in denominators is not explained
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Li 2003
Methods Double-blind randomised placebo-controlled trial to assess the efficacy of oseltamivir in the treatment of
naturally occurring influenza. Background rates of infections are not described, nor strains isolated from
participants are described
Participants Four hundred and seventy eight healthy adults aged 18 to 65 with symptoms consistent with influenza
(fever of 37. 8 degrees C or more, plus at least two others: coryza/nasal congestion, sore throat, cough,
myalgia/muscles aches and pain, fatigue, headache or chills/sweats). People with influenza vaccination less
than 12 months before the study were excluded. Sixteen participants were lost to follow up or refused
to continue the trial, 3 were excluded prior to taking medication because they did not meet the entry
criteria, and 8 were excluded because of protocol violation. Four hundred and fifty one individuals were
analyzed for efficacy as the ITT population (216 oseltamivir and 235 placebo) with 273 individuals were
identified as influenza infected through laboratory test and were regarded as the ITTI population (134
oseltamivir and 139 placebo). For the safety analysis, 459 individuals were included (137 oseltamivir
group with influenza, 84 oseltamivir group without influenza, 141 placebo group with influenza, and 97
placebo group without influenza)
Interventions Oral oseltamivir phosphate or placebo (Roche) 75 mg bid for 5 days
Outcomes Serological:
culture or serological tests were used to confirm influenza cases (symptoms and a positive culture on day
1 and/or = 4 fold increase in HAI antibody between baseline and day 21 of the study). Viral cultures were
performed on all participants: 224 positive and 254 negative. Of 224 individuals with positive culture,
serumHAI antibodies on days 1 and 21 were completed in 160 individuals (133 positive, 27 negative). Of
254 with negative cultures, HAI antibodies were completed in 146 individuals (58 positive, 88 negative)
.
Effectiveness:
the primary outcome was time to resolution of symptoms (from the onset of symptoms to the time that all
symptoms were resolved). A symptom severity scale was used (0 = no problem, 1 = minor, 2 = moderate,
3 = severe). Symptoms scores are reported as median areas under the curve of decreased total score and
cumulative alleviation proportion by arm as survival curve Logrank test
Safety:
nausea, upset upper abdomen, vomiting, vertigo, insomnia, and rash were reported with an increased
frequency in the active arm but the difference was not significant. Numerators are not reported.
Follow up took place at days 3, 6, 8 and 21 (vital signs and laboratory examinations included blood
routine, urine routine, liver and renal function)
Notes The authors conclude that oseltamivir is well tolerated and efficacious in relieving symptoms within 36
of onset of influenza and could be used routinely on all symptomatic subjects during an outbreak. A very
badly reported trial, with impenetrable outcome reporting
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Makela 2000
Methods Randomised double-blind, placebo-controlled trial to assess the effectiveness of zanamivir in the treatment
of subjects presenting with influenza symptoms during a period of influenza activity. The trial took place
in 11 European countries during the winter of 1997-1998. The predominant strain was A/H3N2. Follow
up was up to 28 days
Participants Three hundred and fifty six patients aged 12 or more. Patients presenting with acute febrile influenza-
like illness. Patients were required to have a fever (37.8C or more for patients aged less than 65, 37.2C
or more for patients aged 65 or more, with at least two of the following symptoms: headache, myalgia,
cough and sore throat. They had to start therapy within 2 days of symptom onset. Women who were
pregnant or at risk of pregnancy were excluded
Interventions Within two days of onset of typical influenza symptoms and received orally inhaled zanamivir 10 mg via
diskhaler twice daily for five days or matching placebo
Outcomes Serological:
influenza was confirmed by diagnosis of virus culture, virus isolation, seroconversion, or by virus detection
PCR. Influenza A subtyping was performed by serology and PCR
Effectiveness:
time until alleviation of clinically significant symptoms of influenza
time to alleviation and no use of relief medication, time to return to normal activities
influenza
high risk influenza positive
Safety:
bronchitis
sinusitis
diarrhoea
pharyngitis
nausea and vomiting
pneumonia
Notes The authors conclude that zanamivir is effective in reducing the duration and severity of influenza illness
and is well tolerated. No age breakdown is given and the whole text gives the idea of careful editing to
enhance effect of zanamivir. Reporting of clinical outcomes is in the format of Area Under the Curve
(AUC)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Matsumoto 1999
Methods Double-blind, randomised, placebo-controlled trial of the treatment efficacy of inhaled and intranasal
zanamivir for five days. Follow up was up to 28 days. ITT analysis was carried out. The study was carried
out in 28 centres in Japan during January to March 1995. The dominant strain was A/H3N2
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Matsumoto 1999 (Continued)
Participants One hundred and sixteen healthy subjects aged 16 to 65 recruited in 28 centres randomised to three arms.
Participants with a set list of symptoms who presented themselves to their family doctor within 36 hours
of onset were enrolled. Two participants dropped out from arm 1 and 2 from arm 3 because of lack of
improvement
Interventions Zanamivir (Nippon Glaxo) dry powder (5 mg/inhalation) or matching placebo or aqueous intranasal
spray (1.6 mg/spray) or matching placebo were administered. Participants received either two inhalations
(10mgs) plus intranasal placebo, or 10 mg inhaled zanamivir plus two spray per nostril (6.4 mg) or double
placebo for five days. As initial analysis failed to detect any difference between arm 1 and arm 2, the data
from the two arms was compared with placebo
Outcomes Serological:
serology and virological samples were taken and influenza viruses identified with PCR.
Effectiveness:
participants were instructed in the use of diaries to record symptoms.
- Time to alleviation of:
fever, headache and myalgia, cough and sore throat (used in the text as corporate indicator of lower fever,
headache and myalgia).
- Time to resumption of normal activities
Safety:
possible adverse events
hoarse voice,
headache,
diarrhoea
Notes The authors conclude that participants in the active arms recovered faster by one day compared to placebo
recipients (3 days instead of four).
Continuous outcomes are summarised in the text either median and interquartile ranges (time to allevi-
ation) or as Kaplan-Meyer plots (time to resumption of normal activities). Average reporting quality but
randomisation and double blinding are not described
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
MIST 1998
Methods Multi-centre randomised placebo-controlled trial of the treatment and safety effects of zanamivir in healthy
adults with ILI and influenza. Randomisation and allocation were centralised. Concealment was by means
of sealed envelopes on site. Follow upwas 28 days and symptoms were self-recordedwith diaries. The study
was conducted in 1997 in Australia, New Zealand and South Africa, with A/H3N2 being the dominant
viral strain
Participants Four hundred and fifty five healthy and non-pregnant persons aged 12 or more (mean 37 years) with
influenza symptoms of no more than 36 h (temp of higher than 37.8 degrees C or feverishness or both
and at least two of the following myalgia, sore throat, cough, headache). There were 76 participants
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MIST 1998 (Continued)
(57 with respiratory diseases,15 aged 65 or more, 11 with a metabolic disease, 8 hypertensives and 2
immunocompromised)
There were 58 withdrawals: 31 for adverse events (27 in the zanamivir arm and 4 on placebo), withdrawn
consent (5 and 3), loss to follow up (7 and 10) and 2 because of protocols violation (1 and 1)
Interventions Inhaled zanamivir 10 mg bd or placebo for five days. An antipyretic and antitussive were also dispensed
with a request not be used routinely
Outcomes Serological/Laboratory:
viral cultures and paired antibody titre estimations
Effectiveness:
symptoms (duration and severity): feverishness, cough, headache, sore throat, myalgia, nasal congestion,
weakness and anorexia were rated on a 4-point scale (0 = no symptoms; 1 = mild; 2 = moderate; 3 =
severe)
temp
sleep disturbance
ability to perform normal activity
complications
antibiotic use
Safety:
adverse events
bronchitis
cough
sinusitis
LRTC
diarrhoea
nausea and vomiting
Notes The authors conclude that zanamivir was effective and well-tolerated. A well reported study although
safety outcome definitions are not given and it is difficult to see how adv events such as bronchitis could
be distinguished from influenza disease. The format of reporting of outcomes ay lead to considerable loss
of data
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Monto 1999a
Methods Double-blind randomised, placebo-controlled trial assessing the effects of zanamivir, administered once
daily, in the prevention of influenza infection and disease. Follow up was for 35 days. Randomisation
was stratified in blocks of 10 for each site and participant were assigned sequentially to pre-randomised
packaged drug or placebo. The study was conducted during the 1997-1998 influenza season in two
Midwest university communities, United States (Universities of Michigan and Missouri). A/Sydney/5/97
H3N2 was the dominant strain
Participants One thousand one hundred and seven healthy adults, mean age 29, range 18 to 69 years, mainly students
or community volunteers. 1107 included in the ITT analysis. Eleven discontinued the trial for adverse
events, 16 for consent withdrawal or loss to follow up. Follow up was for up to 28 days with a final visit
at day 35
Interventions Zanamivir 10 mg or placebo for six days or more up to 28 days, administered by self-activating inhalation
once daily using a Diskhaler device
Outcomes Serological/Laboratory:
serum samples and paired sera for antibody titres
Effectiveness:
influenza if had 2 of the following recorded successively in at least 3 diary entries: cough, headache, sore
throat, myalgia, feverishness or temp of at least 37.8 C with a rise in antibody titres and/or viral isolation
febrile influenza if temp of at least 37.8 degrees C with a rise in antibody titres and/or viral isolation
febrile illness if only temp of at least 37.8 degrees C
Safety is not mentioned in detail, only as any adverse event
Notes The authors conclude that zanamivir administered once daily is efficacious and well tolerated in the
prevention of influenza for a 4-week period in healthy adults. A reasonably reported study
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Monto 1999b
Methods Double-blind randomised placebo-controlledmulti-centre parallel group study. Follow upwas for 21 days.
The study was conducted in November to March 1996 in North America and Europe. The dominant
strains were A/H3N2 and A/H1N1
Participants One thousand two hundred and fifty six healthy patients, aged 13 years or more (mean around 35 to
36 years) who had symptoms of influenza up to 48 h duration were enrolled. See below for definition
of symptoms. There were seventy four withdrawals, these were for adverse events, lost to follow up and
other reasons. Seven hundred and twenty two (57%) participants were found to have influenza. There
were 158 participants described as high risk (n = 69 with asthma; n = 31 with cardiovascular disease; n =
18 had metabolic conditions; n = 39 were aged 65 or more
Interventions Zanamivir 10 mg 2 x daily by oral inhalation plus 6.4 mg 2 x daily nasal spray versus zanamivir 10 mg
4 x daily by oral inhalation plus 6.4 mg 4 x daily by nasal spray versus placebo by both routes 2 x daily
versus placebo by both routes 4 x daily. Placebo groups were combined for analysis. Medication was self
38Neuraminidase inhibitors for preventing and treating influenza in healthy adults (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Monto 1999b (Continued)
administered and patients were instructed to take the inhaled medication before the intranasal medication.
All patients were provided with acetaminophen tablets and dextromethorphan cough suppressant but were
instructed to avoid using these medications unless their symptoms became sufficient to warrant them
Outcomes Serological:
serum assays at days 1 and 21 and viral isolation from airways
Effectiveness:
oral temp
severity of symptoms: rated on six point scale in which ’0’ corresponded to no symptoms and ’5’ corre-
sponded to severe symptoms
sleep disturbances
level of ability to perform normal activities
health questionnaire
time to alleviation of clinically significant symptoms, defines as the absence of feverishness, a temperature
less than 37.8C and a score of 0 (none) or 1 (mild) for other major symptoms (i.e., headache, myalgia,
sore throat and cough) for at least 24 hrs or more
time to return to normal activities
use of acetaminophen and cough mixture to relieve symptoms
Safety
Diarrhoea
Nausea and vomiting
Nasal signs and symptoms
Headaches
Bronchitis
Withdrawal due to possible adverse events
Notes The authors conclude that zanamivir can significantly reduce the duration and overall symptomatic effect
of influenza. A summarily reported trial with selective and heterogeneous reporting of outcomes
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Monto 2002
Methods Double-blind randomised placebo controlled PEP trial
Participants Four hundred and eighty seven households with 1291 contacts aged 5 or more (mean age around 19 years)
Interventions Inhaled zanamivir 10mgs once daily for ten days. Index patients with ILI received symptomaticmedication
only
Outcomes Serological: serum assays, PCR and culture (with resistance assay)
Effectiveness: ILI
Efficacy: Influenza
Safety: not better defined but authors report a profile similar to placebo (no cases of bronchospasm are
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Monto 2002 (Continued)
reported in the intervention arm, but two are reported in the placebo arm)
Notes The authors conclude that zanamivir is effective in prophylaxis and interrupting transmission (79% ef-
fectiveness and 81% efficacy - 64% to 90% - for households and 82% for individuals and was well toler-
ated. Zanamivir shortened duration of illness by 1.5 days. No viral resistance was reported. A reasonably
reported trial
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Nicholson 2000
Methods (WV 15670).
Randomised double-blind placebo-controlled preventive phase IIIa trials of Ro 64-0796. WV 15670 was
conducted in Europe, Canada and China during the 1997-1998 winter. 473 otherwise healthy individuals
who presented with at least on respiratory and one constitutional symptom were randomised within 36
hours of onset. AH3N2 was the dominant strain
Participants Seven hundred and twenty six healthy (apart from ILI symptoms) participants aged 18 to 65 were enrolled.
Four hundred and seventy five participants had influenza (161, 158, 156 respectively).
There were seven withdrawals for lack of compliance and 15 because of adverse events and 23 protocol
violations
Interventions Either oseltamivir 75 mg daily orally (n = 155), or twice daily (n = 157), or “matching” placebo (n = 161)
for five days
Outcomes Serological:
culture and serological specimens were used to diagnose influenza infection.
Effectiveness:
the main outcome was the time to alleviation of symptoms expressed in days and type and incidence of
adverse events. Additionally severity of illness was also assessed by means of a symptom score and antibiotic
use was recorded in each arm.
influenza was defined as viral isolation and/or antibody titre (at 3/52 interval) increase. The laboratory
assessment was done in a blinded fashion
Safety:
nausea
vomiting (reported as mean frequencies by arm).
all outcomes were assessed twice daily for 21 days
Notes The authors conclude that the time to alleviation of symptoms was significantly reduced in the active
arms. Equally there was a 30% reduction in the symptoms scores of the active arms of both trials.
As in the prophylaxis/prevention trials of oseltamivir, nausea was themost reported systemic adverse event,
especially at the higher dose. The methodological quality of the study is reasonable. Randomisation by
centralised computer and robust allocation concealment procedures are explicitly mentioned in the text
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Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Puhakka 2003
Methods Multi-centre double-blind randomised placebo-controlled trial of treatment effects of zanamivir in Finnish
armed forces conscripts
Randomisation was computerised in blocks of 6. Only investigator-prescribed paracetamol was allowed.
The studywas conducted (2000-2001) over two influenza seasonswith A/H3N2 andA/H1N1 respectively
as dominant strains
Participants Five hundred and eighty eight conscripts aged around 19 and mainly males, presenting with symptoms
of ILI of less than 48 h duration with a temp of 38C or more and at least 2 of the following: headache,
muscle/joint aches sore throat or cough during periods of influenza viral circulation.
Surveillance was carried out throughout the influenza season. Diary cards were kept by participants for
28 days
Interventions Inhaled zanamivir 5 mg per inhalation or placebo (lactose powder) bid for 5 days
Outcomes Laboratory:
real-time PCR, nasal and throat swabs (at 0, 8, 24 and 48h) and antibody titres (days 1 and 28) were
collected
Effectiveness:
time to alleviation of symptoms (temp less than37.8Cand feverishness score as “none” andother symptoms
recorded as 0 or 1 for 24 h)
time to alleviation of symptoms with no use of relief medication (temp less than 37.8C and feverishness
score as “none” and other symptoms recorded as 0 or 1 for 24 h in patients who have not taken relief
medication)
viral load
use of relief medication
severity of symptoms (overall symptoms, headache, cough, feverishness, sore throat, anorexia, muscle/
joint aches and pains, weakness; on a scale: 0 = no symptoms; 1 = mild; 2 = moderate; 3 = severe)
Complications:
use of antibiotics for complications
use of diagnostic procedures
general well being was assessed using the - measure yourself medical outcomes - MYMOP questionnaire
Safety:
ILI symptoms that got worse
bronchitis
COPD or asthma that got worse
Acceptability:
ease of use of diskhaler device (data not extracted)
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Notes The authors conclude that zanamivir significantly reduces viral load, however startling improvements in
symptoms could not be observed because of the characteristics of this very healthy population. In the
discussion the authors observe the short and benign duration of the illness (median 2.33 d in the placebo
arm). A reasonably reported study with no mention of blinding procedures. Data are not reported for a
number of outcomes (for example, general well-being, use of relief medication, etc) for which data were
apparently collected
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Treanor 2000
Methods (WV 15671)
Multicentre double-blind placebo-controlled randomised trial of the efficacy of oseltamivir in cases of
influenza of 36 hours’ duration or more. Randomisation and allocation were centralised through an
automated phone programme. Although the aim of the study is to test the efficacy of the drug, data for
both efficacy influenza) and effectiveness (ILI) are reported. The study was conducted between January
and March 1998 in the USA. A/H3N2 was the dominant viral strain
Participants Six hundred and twenty nine unvaccinated previously healthy adults aged 18 to 65 presenting within 36
h of symptom onset (oral temp 38 degrees C or more and at least one of the following: cough, sore throat,
nasal symptoms and headache, malaise, myalgia, sweats/chills, fatigue). There were 46 withdrawals (16,
19 and 11 respectively)
Follow up was 21 days, with twice daily observations recorded on diaries
Interventions Oral oseltamivir 75 mg or 150 bd or placebo for 5 days
Outcomes Serological/laboratory:
viral culture for airway swabs and antibody titres at days 1 and 21
Effectiveness:
symptom severity (graded on a 4 point scale)
ability to perform usual activities and health status (11-point visual analogue scales)
oral temp
number and type of complications
Safety:
nausea
vomiting
withdrawals due to adverse effects
Notes The authors conclude that oseltamivir reduces duration of illness and may reduce complications. Convo-
luted reporting and extensive use of medians may lead to loss of important data
Risk of bias
Item Authors’ judgement Description
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Allocation concealment? Yes A - Adequate
Welliver 2001
Methods Multicentre double-blind placebo-controlled cluster randomised controlled trial (C-RCT) of the effects
of oseltamivir in the interruption of transmission of influenza in families. The study was conducted in
the winter of 1989-1999 in North America and Europe (76 centres)
Participants Three hundred and seventy four households (962 healthy contacts with a mean age of 33, minimum 2
members and maximum 8 members per household) of 377 index cases (ICs) presenting within 48h of
onset of cough and coryza. Children aged up to 12 were enrolled only if other contacts in the household
met the enrolment criteria.
A household represented a cluster (all members were randomised to the same treatment).
There were 4 withdrawals due to contact not taking study medication and 7 withdrawals due to adverse
events (5 in the active and 2 in the placebo arm)
Interventions Oseltamivir 75 mg die or placebo within 48 h of symptom onset for 7 days and 500 mg of acetaminophen
if needed. ICs were not treated
Outcomes Serological:
nasal swabs and paired antibody titres
Effectiveness:
proportion of contacts of IC with influenza within days 1 to 7 of the intervention
ILI (oral temp of 37.2 degrees C or more and at least cough, nasal congestion or sore throat and headache,
fatigue, chills or myalgia within 24 h)
influenza (ILI plus laboratory confirmation)
Safety:
GI adverse events
nausea
withdrawals due to adverse events
Notes The authors conclude that oseltamivir was well tolerated and prevented spread of influenza. Poor reporting
of randomisation, cluster correlation calculations and allocation procedures
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
h: hour
ENT: ear, nose and throat
bd: twice daily
bid: twice daily
d: day
ILI: influenza-like illness
ITTI: intention-to-treat index
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ITTII: intention-to-treat index-infected
IC: index cases
ITTIINAB: intention-to-treat index-infected virus-negative at baseline
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ambrozaitis 2005 Prevention of transmission placebo-controlled RCT in elderly in long term care facilities
Aoki 2003 No control arm (Roche study code WV 76006)
Barroso 2005 Viral challenge study on new NI peramivir
Bettis 2006 Data from 1997-1999 registration studies already in review
Bijl 2007 No data presented
Blumentals 2007 Contains retrospective, observational data
Calfee 1999 Experimental influenza only
Cass 1999 No denominator breakdown by arm
Fuyuno 2007 News piece
Hama 2008 Review of Phase IV data
Hayden 1999b Experimental influenza only
Hayden 2000b Experimental influenza only
Ison 2003 Population of persons with underlying medical conditions
Kaiser 2003 Unable to determine the number of healthy adults experiencing complications in each study nor the number of
patients experiencing one of more of “bronchitis, lower respiratory tract infection, or pneumonia” presenting to
each study
Kawai 2005 Prospectve cohort study non comparative with all oseltamivir exposure
Kawai 2006 Non comparative cohort study
Kawai 2007a Porospective cohort study all treated with zanamivir
Kawai 2007b Retrospective cohort
Kawai 2007c Non comparative study with sole exposure to oseltamivir
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Kawai 2008 Prospective cohort study with oseltamivir versus nothing
LaForce 2007 Placebo controlled RCT in elderly
Li 2001 Same data set as Li 2003
Li 2004 Redundants publication of Li 2003
Lin 2006 Very small RCT high risk oseltamivir versus do-nothing
Macfarlane 2005 Editorial
Massarella 2000 Phase 2a study with no safety outcomes reported
Monto 1999c Meta-analysis. No original data presented
Murphy 2000 At risk participants
Peng 2000 Dose-ranging study
Sato 2005 Children admitted to hospital with A/B diagnosis subsequently randomised to oseltamivir, zanamivir, or do-
nothing
Sato 2008 Prospective cohort study in children
Toovey 2008 Review. Contains retrospective, observational data
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D A T A A N D A N A L Y S E S
Comparison 1. NI versus placebo for prophylaxis
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Influenza-like illness 4 3549 Risk Ratio (M-H, Random, 95% CI) 0.92 [0.59, 1.44]
1.1 Oral oseltamivir 75 mg
daily
2 1088 Risk Ratio (M-H, Random, 95% CI) 1.28 [0.45, 3.66]
1.2 Oral oseltamivir 150 mg
daily
1 779 Risk Ratio (M-H, Random, 95% CI) 1.00 [0.25, 3.95]
1.3 Inhaled zanamivir 10 mg
daily
2 1299 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.49, 1.19]
1.4 Intranasal zanamivir 0.32
mg daily
1 189 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.21, 2.95]
1.5 Inhaled and intranasal
zanamivir 10 mg and 0.32 daily
1 194 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.07, 1.58]
2 Influenza (symptomatic) 4 3549 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.23, 0.48]
2.1 Oral oseltamivir 75 mg
daily
2 1087 Risk Ratio (M-H, Random, 95% CI) 0.24 [0.12, 0.48]
2.2 Oral oseltamivir 150 mg
daily
1 780 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.11, 0.67]
2.3 Inhaled zanamivir 10 mg
daily
2 1299 Risk Ratio (M-H, Random, 95% CI) 0.33 [0.18, 0.59]
2.4 Intranasal zanamivir 0.32
mg daily
1 189 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.25, 2.37]
2.5 Inhaled and intranasal
zanamivir 10 mg and 0.32 daily
1 194 Risk Ratio (M-H, Random, 95% CI) 0.66 [0.17, 2.53]
3 Influenza (symptomatic and
asymptomatic)
4 3549 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.49, 0.76]
3.1 Oral oseltamivir 75 mg
daily
2 1087 Risk Ratio (M-H, Random, 95% CI) 0.46 [0.31, 0.68]
3.2 Oral oseltamivir 150 mg
daily
1 780 Risk Ratio (M-H, Random, 95% CI) 0.48 [0.29, 0.80]
3.3 Inhaled zanamivir 10 mg
daily
2 1299 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.50, 0.91]
3.4 Intranasal zanamivir 0.32
mg daily
1 189 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.54, 2.08]
3.5 Inhaled and intranasal
zanamivir 10 mg and 0.32 daily
1 194 Risk Ratio (M-H, Random, 95% CI) 0.77 [0.38, 1.56]
4 Influenza (asymptomatic) 3 2974 Risk Ratio (M-H, Random, 95% CI) 0.83 [0.62, 1.12]
4.1 Oral oseltamivir 75 mg
daily
2 1087 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.43, 1.26]
4.2 Oral oseltamivir 150 mg
daily
1 780 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.35, 1.28]
4.3 Inhaled zanamivir 10 mg
daily
1 1107 Risk Ratio (M-H, Random, 95% CI) 0.98 [0.65, 1.47]
5 Adverse events - nausea 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
46Neuraminidase inhibitors for preventing and treating influenza in healthy adults (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5.1 Oral oseltamivir 75 mg
daily
2 1088 Odds Ratio (M-H, Random, 95% CI) 1.79 [1.10, 2.93]
5.2 Oral oseltamivir 150 mg
daily
1 779 Odds Ratio (M-H, Random, 95% CI) 2.29 [1.34, 3.92]
6 Adverse events - vomiting 2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Oral oseltamivir 75 mg
daily
2 1088 Odds Ratio (M-H, Random, 95% CI) 2.28 [0.87, 5.95]
6.2 Oral oseltamivir 150 mg
daily
1 780 Odds Ratio (M-H, Random, 95% CI) 3.57 [0.81, 15.82]
7 Adverse events - diarrhoea 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Oral oseltamivir 75 mg
daily
1 308 Odds Ratio (M-H, Random, 95% CI) 0.58 [0.28, 1.20]
8 Adverse events - abdominal pain 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Oral oseltamivir 75 mg
daily
1 308 Odds Ratio (M-H, Random, 95% CI) 0.99 [0.49, 1.97]
9 Adverse events - others 1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Oral oseltamivir 75 mg
daily
1 308 Odds Ratio (M-H, Random, 95% CI) 0.95 [0.59, 1.55]
10 Adverse events - withdrawals
due to gastrointestinal events
1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Oral oseltamivir 75 mg
daily
1 779 Odds Ratio (M-H, Random, 95% CI) 3.51 [0.18, 68.21]
10.2 Oral oseltamivir 150 mg
daily
1 780 Odds Ratio (M-H, Random, 95% CI) 3.52 [0.18, 68.47]
Comparison 2. NI versus placebo for treatment
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Time to alleviation of symptoms
(ITT)
9 4985 Hazard ratio (Random, 95% CI) 1.22 [1.14, 1.31]
1.1 Zanamivir 6 3188 Hazard ratio (Random, 95% CI) 1.24 [1.13, 1.36]
1.2 Oseltamivir 3 1797 Hazard ratio (Random, 95% CI) 1.20 [1.06, 1.35]
2 Time to alleviation of symptoms
(influenza cases only)
11 3491 Hazard ratio (Random, 95% CI) 1.32 [1.26, 1.38]
2.1 Zanamivir 7 2117 Hazard ratio (Random, 95% CI) 1.33 [1.29, 1.37]
2.2 Oseltamivir 4 1374 Hazard ratio (Random, 95% CI) 1.30 [1.13, 1.50]
3 Time to return to normal activity
(ITT)
4 2454 Hazard ratio (Random, 95% CI) 1.26 [1.14, 1.40]
3.1 Zanamivir 3 1827 Hazard ratio (Random, 95% CI) 1.28 [1.13, 1.45]
3.2 Oseltamivir 1 627 Hazard ratio (Random, 95% CI) 1.23 [1.02, 1.48]
4 Time to return to normal activity
(influenza cases only)
4 1234 Hazard ratio (Random, 95% CI) 1.22 [1.07, 1.39]
4.1 Zanamivir 3 860 Hazard ratio (Random, 95% CI) 1.17 [1.00, 1.37]
4.2 Oseltamivir 1 374 Hazard ratio (Random, 95% CI) 1.34 [1.07, 1.67]
5 Complications - all types (ILI
cases only)
1 79 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.24, 1.19]
5.1 Zanamivir 1 79 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.24, 1.19]
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6 Complications - all types
(influenza cases only)
4 1122 Risk Ratio (M-H, Random, 95% CI) 0.68 [0.46, 1.00]
6.1 Zanamivir 1 277 Risk Ratio (M-H, Random, 95% CI) 0.73 [0.50, 1.06]
6.2 Oseltamivir 3 845 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.23, 1.37]
7 Complications - all types (ITT) 1 356 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.49, 0.96]
7.1 Zanamivir 1 356 Risk Ratio (M-H, Random, 95% CI) 0.69 [0.49, 0.96]
8 Adverse events - cough 3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
8.1 Zanamivir 2 1043 Odds Ratio (M-H, Random, 95% CI) 1.40 [0.14, 13.49]
8.2 Oral oseltamivir 150 mg
daily
1 273 Odds Ratio (M-H, Random, 95% CI) 1.31 [0.53, 3.22]
9 Adverse events - headache 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
9.1 Zanamivir 2 1352 Odds Ratio (M-H, Random, 95% CI) 0.87 [0.39, 1.97]
9.2 Oral oseltamivir 150 mg
daily
2 586 Odds Ratio (M-H, Random, 95% CI) 0.91 [0.44, 1.87]
10 Adverse events - diarrhoea 5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
10.1 Zanamivir 4 2415 Odds Ratio (M-H, Random, 95% CI) 0.78 [0.37, 1.63]
10.2 Oral oseltamivir 150 mg
daily
1 313 Odds Ratio (M-H, Random, 95% CI) 0.56 [0.28, 1.13]
11 Adverse events - nasal
symptoms (congestion, rhinitis,
dry or sore throat)
4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
11.1 Zanamivir 3 2299 Odds Ratio (M-H, Random, 95% CI) 0.98 [0.47, 2.06]
11.2 Oral oseltamivir 150 mg
daily
1 273 Odds Ratio (M-H, Random, 95% CI) 0.85 [0.51, 1.44]
12 Adverse events - nausea 5 Odds Ratio (M-H, Random, 95% CI) Subtotals only
12.1 Zanamivir 3 2067 Odds Ratio (M-H, Random, 95% CI) 0.63 [0.36, 1.10]
12.2 Oral oseltamivir 150 to
300 mg daily
2 928 Odds Ratio (M-H, Random, 95% CI) 2.50 [1.49, 4.20]
13 Adverse events - vomiting
(Oseltamivir)
2 928 Odds Ratio (M-H, Random, 95% CI) 2.60 [0.77, 8.80]
14 Adverse events - bronchitis or
pneumonia
3 Odds Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Zanamivir 3 2299 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.24, 2.26]
15 Adverse events - all types 4 Odds Ratio (M-H, Random, 95% CI) Subtotals only
15.1 Zanamivir 3 1159 Odds Ratio (M-H, Random, 95% CI) 0.88 [0.69, 1.14]
15.2 Oral oseltamivir 150 mg
daily
1 313 Odds Ratio (M-H, Random, 95% CI) 0.67 [0.43, 1.05]
16 Use of relief medications and
antibiotics
4 1830 Odds Ratio (M-H, Random, 95% CI) 0.82 [0.60, 1.11]
16.1 Zanamivir 2 838 Odds Ratio (M-H, Random, 95% CI) 0.64 [0.41, 1.01]
16.2 Oseltamivir 2 992 Odds Ratio (M-H, Random, 95% CI) 1.01 [0.67, 1.52]
17 Mean nasal viral titres (at 24
hours since randomisation)
4 1002 Mean Difference (IV, Random, 95% CI) -0.62 [-0.82, -0.41]
17.1 Zanamivir 10 to 20 mg
daily
2 441 Mean Difference (IV, Random, 95% CI) -0.40 [-0.75, -0.06]
17.2 Oseltamivir 75 to 150
mg daily
2 561 Mean Difference (IV, Random, 95% CI) -0.73 [-0.99, -0.47]
18 Mean nasal viral titres (at 48
hours since randomisation)
3 659 Mean Difference (IV, Random, 95% CI) -0.63 [-1.13, -0.13]
18.1 Zanamivir 10 to 20 mg
daily
2 441 Mean Difference (IV, Random, 95% CI) -0.71 [-1.58, 0.16]
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18.2 Oseltamivir 150 mg daily 1 218 Mean Difference (IV, Random, 95% CI) -0.44 [-0.74, -0.14]
Analysis 1.1. Comparison 1 NI versus placebo for prophylaxis, Outcome 1 Influenza-like illness.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 1 NI versus placebo for prophylaxis
Outcome: 1 Influenza-like illness
Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Oral oseltamivir 75 mg daily
Hayden 1999a 5/520 4/260 9.4 % 0.63 [ 0.17, 2.31 ]
Kashiwagi 2000a 29/155 15/153 27.0 % 1.91 [ 1.07, 3.42 ]
Subtotal (95% CI) 675 413 36.4 % 1.28 [ 0.45, 3.66 ]
Total events: 34 (NI), 19 (Placebo)
Heterogeneity: Tau2 = 0.36; Chi2 = 2.34, df = 1 (P = 0.13); I2 =57%
Test for overall effect: Z = 0.46 (P = 0.64)
2 Oral oseltamivir 150 mg daily
Hayden 1999a 6/520 3/259 8.6 % 1.00 [ 0.25, 3.95 ]
Subtotal (95% CI) 520 259 8.6 % 1.00 [ 0.25, 3.95 ]
Total events: 6 (NI), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 1.0)
3 Inhaled zanamivir 10 mg daily
Kaiser 2000 4/144 2/48 6.2 % 0.67 [ 0.13, 3.53 ]
Monto 1999a 30/553 39/554 32.6 % 0.77 [ 0.49, 1.22 ]
Subtotal (95% CI) 697 602 38.8 % 0.76 [ 0.49, 1.19 ]
Total events: 34 (NI), 41 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
4 Intranasal zanamivir 0.32 mg daily
Kaiser 2000 7/141 3/48 9.3 % 0.79 [ 0.21, 2.95 ]
Subtotal (95% CI) 141 48 9.3 % 0.79 [ 0.21, 2.95 ]
Total events: 7 (NI), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.73)
5 Inhaled and intranasal zanamivir 10 mg and 0.32 daily
Kaiser 2000 3/146 3/48 6.9 % 0.33 [ 0.07, 1.58 ]
Subtotal (95% CI) 146 48 6.9 % 0.33 [ 0.07, 1.58 ]
Total events: 3 (NI), 3 (Placebo)
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(. . . Continued)
Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
Total (95% CI) 2179 1370 100.0 % 0.92 [ 0.59, 1.44 ]
Total events: 84 (NI), 69 (Placebo)
Heterogeneity: Tau2 = 0.10; Chi2 = 8.70, df = 6 (P = 0.19); I2 =31%
Test for overall effect: Z = 0.35 (P = 0.73)
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Analysis 1.2. Comparison 1 NI versus placebo for prophylaxis, Outcome 2 Influenza (symptomatic).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 1 NI versus placebo for prophylaxis
Outcome: 2 Influenza (symptomatic)
Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Oral oseltamivir 75 mg daily
Hayden 1999a 6/520 12/259 14.2 % 0.25 [ 0.09, 0.66 ]
Kashiwagi 2000a 5/155 21/153 14.8 % 0.24 [ 0.09, 0.61 ]
Subtotal (95% CI) 675 412 29.0 % 0.24 [ 0.12, 0.48 ]
Total events: 11 (NI), 33 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 4.10 (P = 0.000041)
2 Oral oseltamivir 150 mg daily
Hayden 1999a 7/520 13/260 16.2 % 0.27 [ 0.11, 0.67 ]
Subtotal (95% CI) 520 260 16.2 % 0.27 [ 0.11, 0.67 ]
Total events: 7 (NI), 13 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0046)
3 Inhaled zanamivir 10 mg daily
Kaiser 2000 4/144 4/48 7.3 % 0.33 [ 0.09, 1.28 ]
Monto 1999a 11/553 34/554 29.7 % 0.32 [ 0.17, 0.63 ]
Subtotal (95% CI) 697 602 37.1 % 0.33 [ 0.18, 0.59 ]
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Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Total events: 15 (NI), 38 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 3.66 (P = 0.00025)
4 Intranasal zanamivir 0.32 mg daily
Kaiser 2000 9/141 4/48 10.4 % 0.77 [ 0.25, 2.37 ]
Subtotal (95% CI) 141 48 10.4 % 0.77 [ 0.25, 2.37 ]
Total events: 9 (NI), 4 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
5 Inhaled and intranasal zanamivir 10 mg and 0.32 daily
Kaiser 2000 6/146 3/48 7.3 % 0.66 [ 0.17, 2.53 ]
Subtotal (95% CI) 146 48 7.3 % 0.66 [ 0.17, 2.53 ]
Total events: 6 (NI), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI) 2179 1370 100.0 % 0.33 [ 0.23, 0.48 ]
Total events: 48 (NI), 91 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 4.16, df = 6 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 5.90 (P < 0.00001)
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Analysis 1.3. Comparison 1 NI versus placebo for prophylaxis, Outcome 3 Influenza (symptomatic and
asymptomatic).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 1 NI versus placebo for prophylaxis
Outcome: 3 Influenza (symptomatic and asymptomatic)
Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Oral oseltamivir 75 mg daily
Hayden 1999a 28/520 27/259 16.0 % 0.52 [ 0.31, 0.86 ]
Kashiwagi 2000a 11/155 29/153 10.1 % 0.37 [ 0.19, 0.72 ]
Subtotal (95% CI) 675 412 26.1 % 0.46 [ 0.31, 0.68 ]
Total events: 39 (NI), 56 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.81 (P = 0.00014)
2 Oral oseltamivir 150 mg daily
Hayden 1999a 27/520 28/260 16.0 % 0.48 [ 0.29, 0.80 ]
Subtotal (95% CI) 520 260 16.0 % 0.48 [ 0.29, 0.80 ]
Total events: 27 (NI), 28 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0048)
3 Inhaled zanamivir 10 mg daily
Kaiser 2000 16/144 9/48 8.0 % 0.59 [ 0.28, 1.25 ]
Monto 1999a 53/553 77/554 31.6 % 0.69 [ 0.50, 0.96 ]
Subtotal (95% CI) 697 602 39.6 % 0.67 [ 0.50, 0.91 ]
Total events: 69 (NI), 86 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.58 (P = 0.010)
4 Intranasal zanamivir 0.32 mg daily
Kaiser 2000 28/141 9/48 9.6 % 1.06 [ 0.54, 2.08 ]
Subtotal (95% CI) 141 48 9.6 % 1.06 [ 0.54, 2.08 ]
Total events: 28 (NI), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
5 Inhaled and intranasal zanamivir 10 mg and 0.32 daily
Kaiser 2000 21/146 9/48 8.8 % 0.77 [ 0.38, 1.56 ]
Subtotal (95% CI) 146 48 8.8 % 0.77 [ 0.38, 1.56 ]
Total events: 21 (NI), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
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Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Total (95% CI) 2179 1370 100.0 % 0.61 [ 0.49, 0.76 ]
Total events: 184 (NI), 188 (Placebo)
Heterogeneity: Tau2 = 0.01; Chi2 = 6.87, df = 6 (P = 0.33); I2 =13%
Test for overall effect: Z = 4.46 (P < 0.00001)
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Analysis 1.4. Comparison 1 NI versus placebo for prophylaxis, Outcome 4 Influenza (asymptomatic).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 1 NI versus placebo for prophylaxis
Outcome: 4 Influenza (asymptomatic)
Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Oral oseltamivir 75 mg daily
Hayden 1999a 22/520 15/259 20.9 % 0.73 [ 0.39, 1.38 ]
Kashiwagi 2000a 6/155 8/153 8.0 % 0.74 [ 0.26, 2.08 ]
Subtotal (95% CI) 675 412 28.9 % 0.73 [ 0.43, 1.26 ]
Total events: 28 (NI), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
2 Oral oseltamivir 150 mg daily
Hayden 1999a 20/520 15/260 20.0 % 0.67 [ 0.35, 1.28 ]
Subtotal (95% CI) 520 260 20.0 % 0.67 [ 0.35, 1.28 ]
Total events: 20 (NI), 15 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
3 Inhaled zanamivir 10 mg daily
Monto 1999a 42/553 43/554 51.1 % 0.98 [ 0.65, 1.47 ]
Subtotal (95% CI) 553 554 51.1 % 0.98 [ 0.65, 1.47 ]
Total events: 42 (NI), 43 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.10 (P = 0.92)
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Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Total (95% CI) 1748 1226 100.0 % 0.83 [ 0.62, 1.12 ]
Total events: 90 (NI), 81 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.26, df = 3 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
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Analysis 1.5. Comparison 1 NI versus placebo for prophylaxis, Outcome 5 Adverse events - nausea.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 1 NI versus placebo for prophylaxis
Outcome: 5 Adverse events - nausea
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Oral oseltamivir 75 mg daily
Hayden 1999a 63/520 19/260 83.8 % 1.75 [ 1.02, 2.99 ]
Kashiwagi 2000a 8/155 4/153 16.2 % 2.03 [ 0.60, 6.88 ]
Subtotal (95% CI) 675 413 100.0 % 1.79 [ 1.10, 2.93 ]
Total events: 71 (NI), 23 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
2 Oral oseltamivir 150 mg daily
Hayden 1999a 76/520 18/259 100.0 % 2.29 [ 1.34, 3.92 ]
Subtotal (95% CI) 520 259 100.0 % 2.29 [ 1.34, 3.92 ]
Total events: 76 (NI), 18 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 3.03 (P = 0.0025)
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Analysis 1.6. Comparison 1 NI versus placebo for prophylaxis, Outcome 6 Adverse events - vomiting.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 1 NI versus placebo for prophylaxis
Outcome: 6 Adverse events - vomiting
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Oral oseltamivir 75 mg daily
Hayden 1999a 13/520 2/260 41.1 % 3.31 [ 0.74, 14.77 ]
Kashiwagi 2000a 7/155 4/153 58.9 % 1.76 [ 0.51, 6.15 ]
Subtotal (95% CI) 675 413 100.0 % 2.28 [ 0.87, 5.95 ]
Total events: 20 (NI), 6 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.41, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.092)
2 Oral oseltamivir 150 mg daily
Hayden 1999a 14/520 2/260 100.0 % 3.57 [ 0.81, 15.82 ]
Subtotal (95% CI) 520 260 100.0 % 3.57 [ 0.81, 15.82 ]
Total events: 14 (NI), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.094)
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Analysis 1.7. Comparison 1 NI versus placebo for prophylaxis, Outcome 7 Adverse events - diarrhoea.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 1 NI versus placebo for prophylaxis
Outcome: 7 Adverse events - diarrhoea
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Oral oseltamivir 75 mg daily
Kashiwagi 2000a 13/155 21/153 100.0 % 0.58 [ 0.28, 1.20 ]
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Analysis 1.8. Comparison 1 NI versus placebo for prophylaxis, Outcome 8 Adverse events - abdominal pain.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 1 NI versus placebo for prophylaxis
Outcome: 8 Adverse events - abdominal pain
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Oral oseltamivir 75 mg daily
Kashiwagi 2000a 18/155 18/153 100.0 % 0.99 [ 0.49, 1.97 ]
0.002 0.1 1 10 500
Favours NI Favours placebo
Analysis 1.9. Comparison 1 NI versus placebo for prophylaxis, Outcome 9 Adverse events - others.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 1 NI versus placebo for prophylaxis
Outcome: 9 Adverse events - others
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Oral oseltamivir 75 mg daily
Kashiwagi 2000a 46/155 47/153 100.0 % 0.95 [ 0.59, 1.55 ]
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Analysis 1.10. Comparison 1 NI versus placebo for prophylaxis, Outcome 10 Adverse events - withdrawals
due to gastrointestinal events.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 1 NI versus placebo for prophylaxis
Outcome: 10 Adverse events - withdrawals due to gastrointestinal events
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Oral oseltamivir 75 mg daily
Hayden 1999a 3/520 0/259 100.0 % 3.51 [ 0.18, 68.21 ]
Subtotal (95% CI) 520 259 100.0 % 3.51 [ 0.18, 68.21 ]
Total events: 3 (NI), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
2 Oral oseltamivir 150 mg daily
Hayden 1999a 3/520 0/260 100.0 % 3.52 [ 0.18, 68.47 ]
Subtotal (95% CI) 520 260 100.0 % 3.52 [ 0.18, 68.47 ]
Total events: 3 (NI), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.41)
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Analysis 2.1. Comparison 2 NI versus placebo for treatment, Outcome 1 Time to alleviation of symptoms
(ITT).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 1 Time to alleviation of symptoms (ITT)
Study or subgroup NI Placebo log [Hazard ratio] Hazard ratio Weight Hazard ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Zanamivir
Hayden 1997 273 144 0.105 (0.1183) 8.9 % 1.11 [ 0.88, 1.40 ]
Makela 2000 174 182 0.405 (0.1183) 8.9 % 1.50 [ 1.19, 1.89 ]
Matsumoto 1999 77 39 0.288 (0.2449) 2.1 % 1.33 [ 0.83, 2.16 ]
MIST 1998 227 228 0.262 (0.1048) 11.4 % 1.30 [ 1.06, 1.60 ]
Monto 1999b 834 422 0.154 (0.0744) 22.5 % 1.17 [ 1.01, 1.35 ]
Puhakka 2003 293 295 0.207 (0.8366) 0.2 % 1.23 [ 0.24, 6.34 ]
Subtotal (95% CI) 54.0 % 1.24 [ 1.13, 1.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.41, df = 5 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 4.48 (P < 0.00001)
2 Oseltamivir
Li 2003 216 235 0.049 (0.0969) 13.3 % 1.05 [ 0.87, 1.27 ]
Nicholson 2000 484 235 0.216 (0.0854) 17.1 % 1.24 [ 1.05, 1.47 ]
Treanor 2000 418 209 0.253 (0.0894) 15.6 % 1.29 [ 1.08, 1.53 ]
Subtotal (95% CI) 46.0 % 1.20 [ 1.06, 1.35 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 2.67, df = 2 (P = 0.26); I2 =25%
Test for overall effect: Z = 2.96 (P = 0.0031)
Total (95% CI) 100.0 % 1.22 [ 1.14, 1.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.32, df = 8 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 5.64 (P < 0.00001)
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Analysis 2.2. Comparison 2 NI versus placebo for treatment, Outcome 2 Time to alleviation of symptoms
(influenza cases only).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 2 Time to alleviation of symptoms (influenza cases only)
Study or subgroup NI Placebo log [Hazard ratio] Hazard ratio Weight Hazard ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Zanamivir
Boivin 2000 17 10 0.642 (0.3987) 0.4 % 1.90 [ 0.87, 4.15 ]
Hayden 1997 173 89 0.223 (0.1483) 2.6 % 1.25 [ 0.93, 1.67 ]
Makela 2000 136 141 0.47 (0.1378) 3.0 % 1.60 [ 1.22, 2.10 ]
Matsumoto 1999 44 29 0 (0.2863) 0.7 % 1.00 [ 0.57, 1.75 ]
MIST 1998 161 160 0.288 (0.016) 64.6 % 1.33 [ 1.29, 1.38 ]
Monto 1999b 481 241 0.241 (0.1) 5.6 % 1.27 [ 1.05, 1.55 ]
Puhakka 2003 222 213 0.153 (0.0959) 6.0 % 1.17 [ 0.97, 1.41 ]
Subtotal (95% CI) 83.0 % 1.33 [ 1.29, 1.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.89, df = 6 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 18.52 (P < 0.00001)
2 Oseltamivir
Kashiwagi 2000a 122 130 0.287 (0.1264) 3.6 % 1.33 [ 1.04, 1.71 ]
Li 2003 134 139 0.036 (0.124) 3.7 % 1.04 [ 0.81, 1.32 ]
Nicholson 2000 314 161 0.32 (0.1048) 5.1 % 1.38 [ 1.12, 1.69 ]
Treanor 2000 245 129 0.379 (0.1095) 4.7 % 1.46 [ 1.18, 1.81 ]
Subtotal (95% CI) 17.0 % 1.30 [ 1.13, 1.50 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.80, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 3.61 (P = 0.00031)
Total (95% CI) 100.0 % 1.32 [ 1.26, 1.38 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 10.77, df = 10 (P = 0.38); I2 =7%
Test for overall effect: Z = 11.37 (P < 0.00001)
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Analysis 2.3. Comparison 2 NI versus placebo for treatment, Outcome 3 Time to return to normal activity
(ITT).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 3 Time to return to normal activity (ITT)
Study or subgroup NI Placebo log [Hazard ratio] Hazard ratio Weight Hazard ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Zanamivir
Matsumoto 1999 77 39 0.405 (0.2664) 4.0 % 1.50 [ 0.89, 2.53 ]
MIST 1998 227 228 0.251 (0.1378) 15.0 % 1.29 [ 0.98, 1.68 ]
Monto 1999b 834 422 0.234 (0.0761) 49.2 % 1.26 [ 1.09, 1.47 ]
Subtotal (95% CI) 68.3 % 1.28 [ 1.13, 1.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 3.83 (P = 0.00013)
2 Oseltamivir
Treanor 2000 418 209 0.204 (0.0948) 31.7 % 1.23 [ 1.02, 1.48 ]
Subtotal (95% CI) 31.7 % 1.23 [ 1.02, 1.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.031)
Total (95% CI) 100.0 % 1.26 [ 1.14, 1.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 3 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 4.38 (P = 0.000012)
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Analysis 2.4. Comparison 2 NI versus placebo for treatment, Outcome 4 Time to return to normal activity
(influenza cases only).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 4 Time to return to normal activity (influenza cases only)
Study or subgroup NI Placebo log [Hazard ratio] Hazard ratio Weight Hazard ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 Zanamivir
Hayden 1997 173 89 0 (0.1483) 20.0 % 1.00 [ 0.75, 1.34 ]
Makela 2000 136 141 0.194 (0.1378) 23.1 % 1.21 [ 0.93, 1.59 ]
MIST 1998 161 160 0.251 (0.1378) 23.1 % 1.29 [ 0.98, 1.68 ]
Subtotal (95% CI) 66.2 % 1.17 [ 1.00, 1.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.66, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.91 (P = 0.056)
2 Oseltamivir
Treanor 2000 245 129 0.289 (0.114) 33.8 % 1.34 [ 1.07, 1.67 ]
Subtotal (95% CI) 33.8 % 1.34 [ 1.07, 1.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.54 (P = 0.011)
Total (95% CI) 100.0 % 1.22 [ 1.07, 1.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.57, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 3.03 (P = 0.0025)
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Analysis 2.5. Comparison 2 NI versus placebo for treatment, Outcome 5 Complications - all types (ILI cases
only).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 5 Complications - all types (ILI cases only)
Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
Makela 2000 7/38 14/41 100.0 % 0.54 [ 0.24, 1.19 ]
Total (95% CI) 38 41 100.0 % 0.54 [ 0.24, 1.19 ]
Total events: 7 (NI), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
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Analysis 2.6. Comparison 2 NI versus placebo for treatment, Outcome 6 Complications - all types
(influenza cases only).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 6 Complications - all types (influenza cases only)
Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
Makela 2000 33/136 47/141 67.8 % 0.73 [ 0.50, 1.06 ]
Subtotal (95% CI) 136 141 67.8 % 0.73 [ 0.50, 1.06 ]
Total events: 33 (NI), 47 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
2 Oseltamivir
Nicholson 2000 1/158 8/161 3.4 % 0.13 [ 0.02, 1.01 ]
Treanor 2000 8/124 14/129 19.3 % 0.59 [ 0.26, 1.37 ]
0.1 0.2 0.5 1 2 5 10
Favours NI Favours placebo
(Continued . . . )
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(. . . Continued)
Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Li 2003 5/134 5/139 9.5 % 1.04 [ 0.31, 3.50 ]
Subtotal (95% CI) 416 429 32.2 % 0.57 [ 0.23, 1.37 ]
Total events: 14 (NI), 27 (Placebo)
Heterogeneity: Tau2 = 0.22; Chi2 = 3.04, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 552 570 100.0 % 0.68 [ 0.46, 1.00 ]
Total events: 47 (NI), 74 (Placebo)
Heterogeneity: Tau2 = 0.02; Chi2 = 3.29, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 1.94 (P = 0.052)
0.1 0.2 0.5 1 2 5 10
Favours NI Favours placebo
Analysis 2.7. Comparison 2 NI versus placebo for treatment, Outcome 7 Complications - all types (ITT).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 7 Complications - all types (ITT)
Study or subgroup NI Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
Makela 2000 40/174 61/182 100.0 % 0.69 [ 0.49, 0.96 ]
Total (95% CI) 174 182 100.0 % 0.69 [ 0.49, 0.96 ]
Total events: 40 (NI), 61 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
0.1 0.2 0.5 1 2 5 10
Favours NI Favours placebo
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Analysis 2.8. Comparison 2 NI versus placebo for treatment, Outcome 8 Adverse events - cough.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 8 Adverse events - cough
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
MIST 1998 9/227 14/228 67.3 % 0.63 [ 0.27, 1.49 ]
Puhakka 2003 3/293 0/295 32.7 % 7.12 [ 0.37, 138.46 ]
Subtotal (95% CI) 520 523 100.0 % 1.40 [ 0.14, 13.49 ]
Total events: 12 (NI), 14 (Placebo)
Heterogeneity: Tau2 = 1.80; Chi2 = 2.45, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Oral oseltamivir 150 mg daily
Li 2003 125/134 127/139 100.0 % 1.31 [ 0.53, 3.22 ]
Subtotal (95% CI) 134 139 100.0 % 1.31 [ 0.53, 3.22 ]
Total events: 125 (NI), 127 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
0.1 0.2 0.5 1 2 5 10
Favours NI Favours placebo
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Analysis 2.9. Comparison 2 NI versus placebo for treatment, Outcome 9 Adverse events - headache.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 9 Adverse events - headache
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
Matsumoto 1999 2/77 0/39 7.1 % 2.62 [ 0.12, 55.83 ]
Monto 1999b 14/814 9/422 92.9 % 0.80 [ 0.34, 1.87 ]
Subtotal (95% CI) 891 461 100.0 % 0.87 [ 0.39, 1.97 ]
Total events: 16 (NI), 9 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
2 Oral oseltamivir 150 mg daily
Kashiwagi 2000a 1/154 2/159 9.0 % 0.51 [ 0.05, 5.72 ]
Li 2003 119/134 124/139 91.0 % 0.96 [ 0.45, 2.05 ]
Subtotal (95% CI) 288 298 100.0 % 0.91 [ 0.44, 1.87 ]
Total events: 120 (NI), 126 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
0.1 0.2 0.5 1 2 5 10
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65Neuraminidase inhibitors for preventing and treating influenza in healthy adults (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.10. Comparison 2 NI versus placebo for treatment, Outcome 10 Adverse events - diarrhoea.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 10 Adverse events - diarrhoea
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
Matsumoto 1999 2/77 2/39 11.6 % 0.49 [ 0.07, 3.64 ]
MIST 1998 2/227 9/228 17.6 % 0.22 [ 0.05, 1.01 ]
Monto 1999b 27/834 11/422 43.9 % 1.25 [ 0.61, 2.55 ]
Puhakka 2003 6/293 6/295 26.8 % 1.01 [ 0.32, 3.16 ]
Subtotal (95% CI) 1431 984 100.0 % 0.78 [ 0.37, 1.63 ]
Total events: 37 (NI), 28 (Placebo)
Heterogeneity: Tau2 = 0.20; Chi2 = 4.52, df = 3 (P = 0.21); I2 =34%
Test for overall effect: Z = 0.66 (P = 0.51)
2 Oral oseltamivir 150 mg daily
Kashiwagi 2000a 14/154 24/159 100.0 % 0.56 [ 0.28, 1.13 ]
Subtotal (95% CI) 154 159 100.0 % 0.56 [ 0.28, 1.13 ]
Total events: 14 (NI), 24 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
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Analysis 2.11. Comparison 2 NI versus placebo for treatment, Outcome 11 Adverse events - nasal
symptoms (congestion, rhinitis, dry or sore throat).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 11 Adverse events - nasal symptoms (congestion, rhinitis, dry or sore throat)
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
MIST 1998 9/227 2/228 16.4 % 4.67 [ 1.00, 21.84 ]
Monto 1999b 19/834 14/422 37.6 % 0.68 [ 0.34, 1.37 ]
Puhakka 2003 35/293 45/295 45.9 % 0.75 [ 0.47, 1.21 ]
Subtotal (95% CI) 1354 945 100.0 % 0.98 [ 0.47, 2.06 ]
Total events: 63 (NI), 61 (Placebo)
Heterogeneity: Tau2 = 0.25; Chi2 = 5.33, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 0.06 (P = 0.95)
2 Oral oseltamivir 150 mg daily
Li 2003 93/134 101/139 100.0 % 0.85 [ 0.51, 1.44 ]
Subtotal (95% CI) 134 139 100.0 % 0.85 [ 0.51, 1.44 ]
Total events: 93 (NI), 101 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
0.1 0.2 0.5 1 2 5 10
Favours NI Favours placebo
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Analysis 2.12. Comparison 2 NI versus placebo for treatment, Outcome 12 Adverse events - nausea.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 12 Adverse events - nausea
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
Makela 2000 3/174 5/182 14.6 % 0.62 [ 0.15, 2.64 ]
MIST 1998 4/227 9/228 21.6 % 0.44 [ 0.13, 1.44 ]
Monto 1999b 20/834 14/422 63.8 % 0.72 [ 0.36, 1.43 ]
Subtotal (95% CI) 1235 832 100.0 % 0.63 [ 0.36, 1.10 ]
Total events: 27 (NI), 28 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.50, df = 2 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
2 Oral oseltamivir 150 to 300 mg daily
Kashiwagi 2000a 8/154 5/159 20.7 % 1.69 [ 0.54, 5.28 ]
Treanor 2000 74/411 15/204 79.3 % 2.77 [ 1.54, 4.96 ]
Subtotal (95% CI) 565 363 100.0 % 2.50 [ 1.49, 4.20 ]
Total events: 82 (NI), 20 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.46 (P = 0.00055)
0.1 0.2 0.5 1 2 5 10
Favours NI Favours placebo
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Analysis 2.13. Comparison 2 NI versus placebo for treatment, Outcome 13 Adverse events - vomiting
(Oseltamivir).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 13 Adverse events - vomiting (Oseltamivir)
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
Kashiwagi 2000a 9/154 7/159 46.8 % 1.35 [ 0.49, 3.71 ]
Treanor 2000 58/411 7/204 53.2 % 4.62 [ 2.07, 10.33 ]
Total (95% CI) 565 363 100.0 % 2.60 [ 0.77, 8.80 ]
Total events: 67 (NI), 14 (Placebo)
Heterogeneity: Tau2 = 0.56; Chi2 = 3.58, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.53 (P = 0.13)
0.01 0.1 1 10 100
Favours experimental Favours control
Analysis 2.14. Comparison 2 NI versus placebo for treatment, Outcome 14 Adverse events - bronchitis or
pneumonia.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 14 Adverse events - bronchitis or pneumonia
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
MIST 1998 7/227 16/228 35.6 % 0.42 [ 0.17, 1.05 ]
Monto 1999b 9/834 11/422 36.0 % 0.41 [ 0.17, 0.99 ]
Puhakka 2003 9/293 3/295 28.4 % 3.08 [ 0.83, 11.51 ]
0.1 0.2 0.5 1 2 5 10
Favours NI Favours placebo
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Analysis 2.15. Comparison 2 NI versus placebo for treatment, Outcome 15 Adverse events - all types.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 15 Adverse events - all types
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
Matsumoto 1999 21/77 9/39 7.9 % 1.25 [ 0.51, 3.07 ]
MIST 1998 83/227 98/228 44.7 % 0.76 [ 0.52, 1.11 ]
Puhakka 2003 77/293 80/295 47.4 % 0.96 [ 0.66, 1.38 ]
Subtotal (95% CI) 597 562 100.0 % 0.88 [ 0.69, 1.14 ]
Total events: 181 (NI), 187 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Oral oseltamivir 150 mg daily
Kashiwagi 2000a 71/154 89/159 100.0 % 0.67 [ 0.43, 1.05 ]
Subtotal (95% CI) 154 159 100.0 % 0.67 [ 0.43, 1.05 ]
Total events: 71 (NI), 89 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.081)
0.1 0.2 0.5 1 2 5 10
Favours NI Favours placebo
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Analysis 2.16. Comparison 2 NI versus placebo for treatment, Outcome 16 Use of relief medications and
antibiotics.
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 16 Use of relief medications and antibiotics
Study or subgroup NI Placebo Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 Zanamivir
Aoki 2000 34/482 26/240 32.7 % 0.62 [ 0.37, 1.07 ]
Matsumoto 1999 51/77 29/39 12.7 % 0.68 [ 0.29, 1.60 ]
Subtotal (95% CI) 559 279 45.4 % 0.64 [ 0.41, 1.01 ]
Total events: 85 (NI), 55 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.053)
2 Oseltamivir
Li 2003 83/134 84/139 39.6 % 1.07 [ 0.65, 1.73 ]
Nicholson 2000 18/484 10/235 15.1 % 0.87 [ 0.39, 1.91 ]
Subtotal (95% CI) 618 374 54.6 % 1.01 [ 0.67, 1.52 ]
Total events: 101 (NI), 94 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
Total (95% CI) 1177 653 100.0 % 0.82 [ 0.60, 1.11 ]
Total events: 186 (NI), 149 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.32, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)
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Analysis 2.17. Comparison 2 NI versus placebo for treatment, Outcome 17 Mean nasal viral titres (at 24
hours since randomisation).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 17 Mean nasal viral titres (at 24 hours since randomisation)
Study or subgroup NI Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Zanamivir 10 to 20 mg daily
Boivin 2000 17 2.19 (1.61) 10 2.79 (1.74) 2.5 % -0.60 [ -1.92, 0.72 ]
Puhakka 2003 212 3.67 (1.95) 202 4.06 (1.81) 33.2 % -0.39 [ -0.75, -0.03 ]
Subtotal (95% CI) 229 212 35.7 % -0.40 [ -0.75, -0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
2 Oseltamivir 75 to 150 mg daily
Nicholson 2000 233 1.6 (1.9) 117 2.3 (2) 22.8 % -0.70 [ -1.14, -0.26 ]
Treanor 2000 140 1.55 (1.2) 71 2.3 (1.1) 41.5 % -0.75 [ -1.07, -0.43 ]
Subtotal (95% CI) 373 188 64.3 % -0.73 [ -0.99, -0.47 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 5.51 (P < 0.00001)
Total (95% CI) 602 400 100.0 % -0.62 [ -0.82, -0.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.30, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 5.78 (P < 0.00001)
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Analysis 2.18. Comparison 2 NI versus placebo for treatment, Outcome 18 Mean nasal viral titres (at 48
hours since randomisation).
Review: Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Comparison: 2 NI versus placebo for treatment
Outcome: 18 Mean nasal viral titres (at 48 hours since randomisation)
Study or subgroup NI Placebo Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Zanamivir 10 to 20 mg daily
Boivin 2000 17 1.68 (1.53) 10 1.73 (1.55) 13.0 % -0.05 [ -1.25, 1.15 ]
Puhakka 2003 212 2.7 (1.94) 202 3.71 (1.75) 42.0 % -1.01 [ -1.37, -0.65 ]
Subtotal (95% CI) 229 212 55.0 % -0.71 [ -1.58, 0.16 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 2.24, df = 1 (P = 0.13); I2 =55%
Test for overall effect: Z = 1.59 (P = 0.11)
2 Oseltamivir 150 mg daily
Kashiwagi 2000b 106 0.66 (1.03) 112 1.1 (1.2) 45.0 % -0.44 [ -0.74, -0.14 ]
Subtotal (95% CI) 106 112 45.0 % -0.44 [ -0.74, -0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.91 (P = 0.0036)
Total (95% CI) 335 324 100.0 % -0.63 [ -1.13, -0.13 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 6.82, df = 2 (P = 0.03); I2 =71%
Test for overall effect: Z = 2.47 (P = 0.013)
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A P P E N D I C E S
Appendix 1. EMBASE (WebSPIRS) search strategy
#1 explode ’influenza-’ /
#2 (influenza* in ti) or (influenza* in ab)
#3 #1 or #2
#4 explode ’sialidase-inhibitor’ /
#5 (neuraminidase inhibitor* in ti) or (neuraminidase inhibitor* in ab)
#6 explode ’oseltamivir-’ /
#7 (oseltamivir in ti) or (oseltamivir in ab)
#8 explode ’zanamivir-’ /
#9 (ozanamivir in ti) or (zanamivir in ab)
#10 #4 or #5 or #6 or #7 or #8 or #9
#11 #3 and #10
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Appendix 2. Glossary of terms
• Efficacy: the impact of an intervention (drug, vaccines etc) on a problem or disease in ideal conditions - in this case the capacity
of NIs to prevent or treat influenza and its complications.
• Effectiveness: the impact of an intervention (drug, vaccines etc) on a problem or disease in field conditions - in this case the
capacity of NIs to prevent or treat ILI and its complications.
• Influenza: an acute respiratory infection caused by a virus of the Orthomyxoviridae family. Three serotypes are known (A, B and
C). Influenza causes an acute febrile illness with myalgia, headache and cough. Although the median duration of the acute illness is
three days, cough and malaise can persist for weeks. Complications of influenza include otitis media, pneumonia, secondary bacterial
pneumonia, exacerbations of chronic respiratory disease and bronchiolitis in children. These illnesses may require treatment in a
hospital and can be life-threatening especially in ’high-risk’ people e.g. the elderly and people suffering from chronic heart disease.
Additionally, influenza can cause a range of non-respiratory complications including febrile convulsions, Reye’s syndrome and
myocarditis. The influenza virus is composed of a protein envelope around an RNA core. On the envelope are two antigens:
neuraminidase (N antigen) and hemagglutinin (H antigen). Hemagglutinin is an enzyme that facilitates the entry of the virus into
cells of the respiratory epithelium, while neuraminidase facilitates the release of newly produced viral particles from infected cells. The
influenza virus has a marked propensity to mutate its external antigenic composition to escape the hosts’ immune defences. Given this
extreme mutability, a classification of viral subtype A based on H and N typing has been introduced. Additionally, strains are classified
on the basis of antigenic type of the nucleoprotein core (A, B ), geographical location of first isolation, strain serial number and year of
isolation. Every item is separated by a slash mark (e.g. A/Wuhan/359/95 (H3N2)). Unless otherwise specified such strains are of
human origin. The production of antibodies against influenza beyond a conventional quantitative threshold is called seroconversion.
Seroconversion in the absence of symptoms is called asymptomatic influenza.
• Influenza-like illness (ILI): an acute respiratory illness caused by scores of different viruses (including influenza A and B)
presenting with symptoms and signs which are not distinguishable from those of influenza. ILI does not have documented laboratory
isolation of the causative agent and is what commonly presents to physicians and patients (also known as the flu“)
• Mean: a measure of central tendency of a group of variables (such as age). It is calculated by adding all the individual values and
then dividing by the number of values in the group.
• Median: a measure of central tendency of a group of variables (such as age). It is the halfway mark of a set of variables, the
dividing point between lower and upper.
• Randomised study: when it appears that the individuals (or other experimental units) followed in the study were definitely or
possibly assigned prospectively to one of two (or more) alternative forms of health care using random allocation - randomised
controlled trial (RCT). When the unit of allocation is a group (such as a family, or a military unit) the design is that of a Cluster
Randomised Trial (C-RCT).
• Quasi-randomised study: when it appears that the individuals (or other experimental units) followed in the study were
definitely or probably assigned prospectively to one of two (or more) alternative forms of health care using some quasi-random
method of allocation (such as alternation, date of birth or case record number) - clinical controlled trial (CCT)
Appendix 3. Details of previous searches
In the original review, we searched the Cochrane Controlled Trials Register (CCTR) (The Cochrane Library 1999, issue 1), MEDLINE
(in May 1999), EMBASE (1991 to 1998). We read the bibliography of retrieved articles in order to identify further trials. We hand
searched the journal Vaccine from its first issue to the end of 1997. Given that NIs were still at the pre-registration developmental phase,
to locate unpublished trials, we contacted both manufacturers. See below for the original search strategy.
The following search terms or combined sets in any language were used:
Influenza Route (oral)
route (parenteral)
Neuraminidase inhibitors
Oseltamivir
RO/GS 4104
Zanamivir
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In the 2005 update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2005, issue
3), MEDLINE (2004 to September, Week 4 2005), EMBASE (2003 to June 2005). We also contacted manufacturers, researchers in
the field, and authors of studies evaluated in the review.
In the 2008 update, we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2008, issue
2), MEDLINE (2005 to May, Week 4 2008), and EMBASE (2005 to May 2008).
Appendix 4. Adverse effects search strategies
CENTRAL Issue 3, 2009
#1MeSH descriptor Oseltamivir explode all trees
#2MeSH descriptor Zanamivir explode all trees
#3(oseltamivir or zanamivir or GS4071 or tamiflu or relenza):ti,ab,kw
#4neuraminidase NEXT inhibitor*:ti,ab,kw
#5(#1 OR #2 OR #3 OR #4)
#6safe or safety:ti,ab,kw
#7side NEXT effect*:ti,ab,kw
#8(adverse or undesirable or harm* or serious or toxic) NEAR/3 (effect* or reaction* or event* or outcome*):ti,ab,kw
#9MeSH descriptor Product Surveillance, Postmarketing explode all trees
#10MeSH descriptor Adverse Drug Reaction Reporting Systems explode all trees
#11MeSH descriptor Clinical Trials, Phase IV as Topic explode all trees
#12MeSH descriptor Poisoning explode all trees
#13MeSH descriptor Substance-Related Disorders explode all trees
#14MeSH descriptor Drug Toxicity explode all trees
#15MeSH descriptor Abnormalities, Drug-Induced explode all trees
#16MeSH descriptor Drug Monitoring explode all trees
#17MeSH descriptor Drug Hypersensitivity explode all trees
#18(toxicity or complication* or noxious or tolerability):ti,ab,kw
#19MeSH descriptor Case-Control Studies explode all trees
#20MeSH descriptor Cohort Studies explode all trees
#21(#6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20)
#22(#5 AND #21)
#23MeSH descriptor Oseltamivir explode all trees with qualifier: AE
#24MeSH descriptor Zanamivir explode all trees with qualifier: AE
#25(#22 OR #23 OR #24)
EMBASE (Ovid)
1 exp sialidase inhibitor/
2 exp oseltamivir/
3 exp zanamivir/
4 (oseltamivir or zanamivir or GS4071 or tamiflu or relenza).tw.
5 neuraminidase inhibitor*.tw.
6 or/1-5
7 (ae or si or to or co).fs.
8 side effect*.tw.
9 (safe or safety).tw.
10 ((adverse or undesirable or harms* or serious or toxic) adj3 (effect* or reaction* or event* or outcome*)).tw.
11 exp adverse drug reaction/
12 exp drug toxicity/
13 exp drug safety/
14 exp drug monitoring/
15 exp drug hypersensitivity/
16 exp postmarketing surveillance/
17 exp drug surveillance program/
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18 exp phase iv clinical trial/
19 (toxicity or complication* or noxious or tolerability).tw.
20 exp case control study/
21 exp cohort analysis/
22 or/7-21
23 6 and 22
Appendix 5. Doshi’s description of the exclusion of one study (Kaiser 2003)
The story behind the review
Peter Doshi
Program in History, Anthropology, Science, Technology and Society, E51-070, Massachusetts Institute of Technology, Cambridge,
Massachusetts, USA.
Adapted from a BMJ analysis (Doshi 2009)
Since August, our Cochrane review team tried to do one simple thing: obtain the data necessary to verify claims that Tamiflu lowers serious
complications of influenza such as pneumonia. We failed, but in failing, discovered that the public evidence base for this global public health
drug is fragmented, inconsistent, and contradictory. We are no longer sure Tamiflu offers a therapeutic and public health policy advantage over
aspirin. If the public is to trust in public health policies, the scientific basis informing knowledge of the harms and effects of those interventions
must be public and open to independent analysis.
How a Cochrane review turned controversial
Systematic reviews are designed to synthesize the most reliable evidence on the effects of interventions. In retrospect, our Cochrane
review of neuraminidase inhibitors began on a naïve but excited note. I had just received from the FDA a response to my Freedom of
Information Act request, a CDROM containing thousands of postmarketing adverse event reports over the past decade for the two NI
drugs Tamiflu (oseltamivir) and Relenza (zanamivir). The dataset was difficult to interpret, and analysis would require some time (1).
Although the review had last been updated in 2008, our new task was to include a safety assessment component. Tom Jefferson, who
led the review, wrote to the group then just being formed, “Dear Friends, I am writing to inform you that the NHS [National Institute
of Health Research] has commissioned an update of our Cochrane review ... although it is always dangerous to pre-judge the issue, I
expect no new effectiveness data but a lot of pharmacovigilance data.” Two days later, a pediatrician from Japan submitted a comment
to the Cochrane Collaboration that would end up bedevilling our analysis for months (See NI Review Web Extra: Hayashi criticism).
Hayashi pointed out that while Jefferson et al’s previous review (2) found Tamiflu effective in reducing important complications of
influenza such as pneumonia, that conclusion was drawn from a single peer-reviewed study (Kaiser (3)) which itself had meta-analyzed
10 manufacturer-funded trials from the late 1990s, of which only 2 were published in peer reviewed journals (4,5). (The remaining
eight were apparently either unpublished or published in abstract form.) The Hayashi comment exposed the fact that the conclusions
of our review were based on taking the word of other papers on face value. Meeting Hayashi’s challenge required we verify the data for
ourselves.
A maze of inconsistencies
The Hayashi comment set off a series of perplexing discoveries. Despite funding the Kaiser meta-analysis which concluded that
Tamiflu reduces complications, Tamiflu’s manufacturer, Roche, apparently did not itself make any such claims about complications. A
Tamiflu.com webpage reads, “Treatment with TAMIFLU has not been proven to have a positive impact on these outcomes,” referring
to pneumonia other respiratory diseases as well as influenza-related death (6).
Similarly, our Cochrane review of the literature also found both Tamiflu and competitor drug Relenza effective in reducing the duration
of influenza-like illness symptoms. But here again, Roche’s position is that Tamiflu is ineffective against influenza-like illnesses not
caused by influenza (7). US, EU, and Japanese drug regulators agree: Tamiflu only works for true influenza virus infections. (Table)
These inconsistencies were pointing to the uncomfortable conclusion that the Cochrane Collaboration had promoted-by trusting the
validity of other work in the scientific literature-efficacy claims more optimistic than even the drug manufacturer’s.
Reality, however, proved more complex. Roche’s statement that Tamiflu is not proven to reduce complications is apparently a message
onlymeant for Americans. At the bottom of Tamiflu.com webpages is a bold-face note: “THIS [WEB]SITE IS INTENDEDFORU.S.
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AUDIENCES ONLY.” On Roche.com, the global website, the manufacturer boasts that Tamiflu provides a “67 percent reduction in
secondary complications such as bronchitis, pneumonia and sinusitis in otherwise healthy individuals” (8). Statements from regulatory
agencies in Tamiflu’s three chief markets are similarly inconsistent: the EU EMEA mentions benefit, the US FDA denies benefit, and
Japanese PMDA does not discuss complications (Table), raising the question of whether these agencies have evaluated the same datasets.
(Jefferson emailed the EMEA asking for the raw data underlying the endorsement but after three weeks was asked what he meant by
“the raw data”.)
Data pertaining to Tamiflu’s safety were equally confusing. We discovered that FDA’s postmarketing drug safety database known as
AERS (which collects reports of adverse events worldwide of FDA approved pharmaceuticals approved) had fewer total entries than
Roche’s own database held of just neuro-psychiatric classified adverse events (NPAEs). (Of 2466 NPAEs in the Roche Global Safety
Database between 1999 and September 15, 2007, Roche researchers classified 562 “serious” (9). Over this period, the AERS database
only holds 1805 adverse event reports of any kind.)
In publications we trust
Analyzing and learning from publications in the scientific literature is central to contemporary scientific practice. Essential to this
practice is the act of trust. Trust that trials are carried out properly and that published reports are a genuine reflection of that research.
Trust that policymakers accurately read and interpret those reports to make evidence based decisions. Trust, in other words, that claims
about a drug’s performance are backed by hard data. Hayashi’s comment challenging our conclusions revealed the degree to which
Cochrane reviews are fundamentally based on the premise that the published literature can be trusted.
The Cochrane Collaboration was not alone in trusting publications. The Kaiser paper has for several years been the sole citation
offered in US CDC recommendations on influenza in support of the statement that Tamiflu reduces the risk of hospitalization and
pneumonia (10-12). The claim also found its way into US national influenza preparedness documents. The United States HHS
Pandemic Influenza Plan, for example, assumes that in a pandemic, neuraminidase inhibitors “will be effective in decreasing risk of
pneumonia, will decrease hospitalization by about half (as shown for interpandemic influenza), and will also decrease mortality.”(13)
These statements were made despite US regulators saying the opposite.
Or, in secrecy we trust?
Obtaining raw data from properly carried out trials on complications is the only way to resolve the inconsistencies surrounding Tamiflu’s
effect on reducing complications. On behalf of the review team, Jefferson wrote to the authors of the Kaiser paper, but was told that
they no longer had the files and to contact Roche. Jefferson also wrote to authors of the two peer-reviewed published trials used in
Kaiser’s meta-analysis. One responded but once again directed us to the manufacturer.
Jefferson first contacted Roche in early September. On October 2, Roche indicated a willingness to share data, but not openly. It
furnished Jefferson with a “confidentiality agreement,” containing a clause that says that the signee (Jefferson) agrees “not to disclose ...
the existence and terms of this Agreement....” (Web Extra: Roche confidentiality agreement). Roche apparently intended to not only
keep its data concealed, but additionally intended to conceal the fact that it was quieting people through a secrecy clause.
Jefferson never signed the confidentiality agreement, but wrote the next day asking for clarification which he never received. OnOctober
7 the company asked Jefferson to restate which data he was seeking. After Jefferson’s answer, Roche said it was unable to provide data
because it had already provided it for a similar meta-analysis being started by an independent expert influenza group. The Cochrane
request, Roche said, might conflict with that review. In return, Jefferson challenged Roche to outline its concerns and explain why
multiple groups of independent researchers should pose a problem and lead to data exclusivity. Roche did not answer these questions,
but eight days later (October 21), unexpectedly emailed Jefferson excerpts of company reports from all clinical trials used in the Kaiser
meta-analysis. Our team analyzed the data, and Jefferson wrote to Roche explaining that the files were insufficient to verify the effects
on complications claims in Kaiser and the methods used in the trials. Roche responded on October 28, saying it would send more
information the next week. Jefferson informed them that our deadline was now past, but we would accept any additional information
for future updates. (As of November 15, we have heard nothing.)
The 2008 Cochrane review placed its trust in publications, and included Kaiser’s analysis, consequently endorsing the conclusion that
Tamiflu reduces complications such as pneumonia and bronchitis. Once again incorporating the Kaiser paper data into the updated
review, despite our inability to obtain data sufficient to perform an independent analysis of the data, would have shifted our position
from that of trust in publication to that of trust in secrecy. We dropped Kaiser’s paper from our analysis.
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Implications
After four months of seeking the data used to support the claims of Kaiser, we have come up empty-handed. If one is to trust in
the performance of Tamiflu to reduce important complications of influenza such as pneumonia, they must do so trusting that data
supporting those claims exist. Our experience has left us with a doubtful feeling towards placing our trust in drug companies.
We feel equally wary over our conclusion that Tamiflu and Relenza reduce the symptoms of influenza-like illness (ILI), but this is what
our review concludes, incorporating the published trial data. Lack of effectiveness against ILI would be bad news: ILI is the clinical
syndrome usually consisting of fever with cough or sore throat, well known as “the flu.” Without laboratory testing, one cannot know
whether influenza virus or some other agent is causing the patient’s discomfort (14). In past influenza seasons, United States virologic
surveillance data suggest that at peak “flu season” the proportion of respiratory specimens testing positive for influenza reaches 25-35%,
but over the entire season, influenza viruses are found in only a small minority (14%) of tested patients. By contrast, of the patients
with influenza-like illness recruited into the Tamiflu and Relenza trials we analyzed, an incredible 57-80% had influenza (Figure). The
discrepancy appears the likely outcome of a special patient inclusion methodology, in which “Centers were activated to recruit subjects
during an influenza outbreak in the locality, detected using standardized surveillance techniques,” according to the company trial report
excerpts we obtained. This crucial detail, however, was not mentioned in published Tamiflu trials (4,5). If Australia’s winter experience
with A/H1N1 is any guide, influenza is not a majority cause of ILI cases even during a pandemic, and thus NIs may be ineffective for
most patients today (15).
If Tamiflu is no better than placebo in its ability to reduce the complications of influenza, and is also ineffective against non-influenza
ILI, as US and Japanese regulatory documents indicate, Tamiflu’s ability to treat the symptoms of influenza may be similar to that of
an NSAID such as aspirin. This realization led us to call for a head-to-head trial of Tamiflu versus a NSAID.
With respect to safety concerns, FDA reporting rules turn out to have important limitations, namely that although manufacturers are
under mandatory reporting requirements, adverse events occurring outside the United States judged to not meet the “both serious and
unexpected” criteria are under no requirement to be reported. Thus the public AERS database relies on manufacturers to honestly
and accurately judge whether adverse events reported in conjunction with their products are “serious” and therefore must be reported-
or not. In the case of Tamiflu, considering that 75% of Tamiflu’s market has been in Japan, this has important implications on our
knowledge of its safety.
Public Health Drugs
In the ten years since Tamiflu was approved for use in 1999, neither American nor Japanese regulators have approved statements that
the drug lowers rates of influenza-related complications, and one may have in fact even required Roche to declare “Tamiflu has not been
proven to have a positive impact on the potential consequences (such as hospitalizations, mortality, or economic impact) of seasonal,
avian, or pandemic influenza.”(16) Despite the work of these regulators, public health officials trusted the published literature, said
Tamiflu could, and spent billions of dollars building drug stockpiles, elevating Tamiflu to the status of a public health drug.
Public health drugs-like vaccines-get deployed on a population basis, directed by national or international level policy decisions. As
witnessed in the UK, when the government declared that Tamiflu may be used to treat all symptomatic cases even without a physician
consult or laboratory diagnosis, hundreds of thousands of courses of the drug were used in a fortnight (17). Mass prescription carries
serious responsibilities. While the evidence base for all approved drugs should be sound, the evidence base for public health drugs must
be of the highest quality, publicly available and open to independent scrutiny.
Trust is a noble human quality, but evidence based medicine should not hinge upon a singular trust in any one institution, particularly
not in profit-driven companies to report information about their own products free of bias, let alone truthfully. As John Abraham once
observed, there seems a tragic irony in that as pharmaceutical companies do not trust each other, that the public or government should
be asked to trust them. (18) If governments have the authority to purchase and govern the use of multi-billion dollar drug stockpiles,
they should have the interest, time, and money to transparently and independently first verify and evaluate the effects of that drug.
The Box contains some ideas on where to start.
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Table
Effect For Against
Complications of influenza Roche (roche.com): “Tamiflu delivers ... [a] 67
percent reduction in secondary complications
such as bronchitis, pneumonia and sinusitis in
otherwise healthy individuals” (8)
Kaiser: “Our analysis found that early treat-
ment of influenza illness with the neuraminidase
inhibitor oseltamivir significantly reduced in-
fluenza-related LRTCs, associated antibiotic use,
and the risk of hospitalization. This effect was
observed in both at-risk subjects and otherwise
healthy individuals.” (3)
EU: “The proportion of subjects who developed
specified lower respiratory tract complications
(mainly bronchitis) treated with antibiotics was
reduced from 12.7 % (135/1063) in the placebo
group to 8.6 % (116/1350) in the oseltamivir
treated population (p = 0.0012).” (19)
CDC: “In a study that combined data from 10
clinical trials, the risk for pneumonia among
those participants with laboratory-confirmed in-
fluenza receiving oseltamivir was approximately
50% lower than among those persons receiving
a placebo and 34% lower among patients at risk
for complications (p<0.05 for both comparisons)
[(3)].” (12)
HHS: “Treatment with a neuraminidase in-
hibitor (oseltamivir [Tamiflu®] or zanamivir [Re-
lenza®]) will be effective in decreasing risk of
pneumonia, will decrease hospitalizationby about
half (as shown for interpandemic influenza), and
will also decrease mortality.” (13)
Roche (tamiflu.com): “Treatment with TAMI-
FLU has not been proven to have a positive im-
pact on [asthma, emphysema, other chronic lower
respiratory diseases, pneumonia, other respira-
tory diseases, pneumonitis, and influenza-related
death]” (6).
FDA: “Serious bacterial infectionsmay beginwith
influenza-like symptoms or may coexist with or
occur as complications during the course of in-
fluenza. TAMIFLU has not been shown to pre-
vent such complications.” (20)
Japan PMDA: no mention of complications on drug
product information sheet (21)
Influenza-like illness (ILI) Nicholson: “The duration of illness was signifi-
cantly lower in the intention-to-treat [ILI] popu-
lation than in the other subgroups because of the
high proportion of influenza-infected patients in
this population.” (5)
Treanor: “As expected, the greatest benefit of ther-
apy was seen in individuals with evidence of in-
fluenza virus infection. However, analysis of the
entire population also demonstrated a significant
Roche: “We acknowledge that oseltamivir is in-
effective against influenza-like illness caused by
viruses other than influenza.” (7)
EU EMEA: “Oseltamivir is effective only against
illness caused by influenza viruses. There is no
evidence for efficacy of oseltamivir in any illness
caused by agents other than influenza viruses.”
(19)
FDA: “There is no evidence for efficacy of TAM-
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(Continued)
benefit of treatment.” (4)
Previous Cochrane review: “Time to alleviation
of symptoms [for ILI were] … in favour of the
[neuraminidase inhibitor] treated group … (haz-
ard ratio 1.20, 95% CI 1.06 to 1.35).” (22)
IFLU in any illness caused by agents other than
254 influenza viruses Types A and B.” (20)
Japan PMDA: “Tamiflu has no effect against in-
fections except those caused by influenza A and B
viruses.” (21)
Table-Contradictory statements made about the potential benefits of Tamiflu
Box
Clarify expectations and provide evidence for them. Public health policies aiming to employ mass interventions should clearly state
and identify (before approving the policy) the expected harms and benefits of that intervention. For every claim, raw data should
be made available to aid independent analysis of the data. Clarity regarding the expectations of a drug can help reveal important
inconsistencies, flagging them as areas of uncertainty that require better evidence.
Strengthen trial registration processes. All trials should be centrally registered (perhaps with the government in initiatives like
ClinicalTrials.gov) with the names of all key study investigators and their affiliations to help reduce the potential for ghost authorship.
A field for publications resulting from a given trial, as well as a field explaining why a study was not/never published one year past its
completion would help third party investigators match clinical trial to publication, and bring more awareness of the importance of
publishing “negative” results.
Make patient level data available. Individual patient data is often the only way to resolve questions about the effects of a drug.
Publicly available anonymized patient level datasets on regulator websites would increase transparency and enable independent re-
analyses of trial results.
Reduce the reliance on trust. Data collecting methodologies (such as adverse events reporting systems) that rely on companies to self-
evaluate potential harms caused by their drug may lead to bias. Reduce this potential by making mandatory reporting requirement
apply to all known adverse events, allowing the importance of a given adverse event to be determined by anybody who cares to analyze
the publicly accessible post marketing surveillance database. Internet-only based reporting of adverse events would lessen the workload
and help facilitate all known adverse events rapidly find their way into regulatory agency public databases.
Box-A short list of higher standards for evidence-based public health decision making
Figure
Figure-Proportion of respiratory specimens testing positive for influenza during influenza seasons (week 40 to week 20), 1997-98 to
2008-09, and comparison to proportion of intention-to-treat (ITT) population with influenza enrolled in ten Roche clinical trials
reported by Nicholson, Treanor, and Kaiser. Peak weekly influenza positivity rate also shown. Seasonal data are from US CDC.
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F E E D B A C K
Neuraminidase inhibitors for preventing and treating influenza in healthy adults, 16 July 2009
Summary
Dear Mr Jefferson
We have some questions on the conclusion in your Oseltamivir review especially about the prevention of complication. You described
that Oseltamivir 150 mg daily prevented lower respiratory tract complications (OR 0.32, 95% CI 0.18 to 0.57).
However, we have found that this conclusion is based on the other review (Kaiser 2003) and not on your own data analysis. The authors
of the review were four employees of F. Hoffman-La Roche Ltd, one paid consultant to F. Hoffman-La Roche Ltd and Kaiser. We
cannot find any raw data about this conclusion from your review. Kaiser’s review included 10 RCTs; two RCTs (Nicholson 2000 and
Treanor 2003) were published as articles in the peer-reviewed medical journal (JAMA and Lancet), but other 8 RCTs were proceedings
of congress (5 RCTs), abstracts of the congress (one RCT) and meeting (one RCT) and data on file, Hoffmann-La Roche, Inc, Nutley,
NJ (one RCT). The lower respiratory tract complication rates of these articles were summarized on table: there was no significant
difference between Oseltamivir and placebo, and their Odds Ratio’s (ORs) were1.81. But ORs of other 8 RCTs were 4.37. We strongly
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suppose that the reviewer’s conclusion about the complications was mainly determined by these 8 RCTs, we should appraise the 8 trials
rigidly. Without this process it’s difficult to conclude that Osltamivir can prevent lower respiratory tract complications.
Table: All lower respiratory tract complications (influenza case only)
Nicholson 2000 + Treanor 2003
Complications Placebo Oseltamivir 150 mg
+ 13 7
- 277 &#12288; 270
Other 8 RCTs
Complications Placebo Oseltamivir 150mg
+ 22 10
- 350 695
Kaiser (Cochrane)
Complications Placebo Oseltamivir 150mg
+ 35 17
- 627 965
Submitter agrees with default conflict of interest statement: I certify that I have no affiliations with or involvement in any organization
or entity with a financial interest in the subject matter of my feedback.
Reply
Response to Hayashi’s Feedback comment: critical analysis of Kaiser et al (2003)
Kaiser et al (2003) combined 10 randomised control trials (RCTs) comparing oseltamivir with placebo in the treatment of influenza.
They focused on risk of complications leading to antibiotic use. A limitation of their analysis was the combining of bronchitis,
pneumonia and lower respiratory tract infections which they labelled as lower respiratory tract complications (LRTC). In the original
trials complications studied also included sinusitis and otitis media however these were ignored in the Kaiser et al study. In addition
bronchitis is a very general diagnosis whereas pneumonia is more specific and a much more serious condition. Combining of these two
outcomes is questionable. Another limitation of the Kaiser et al study involves their choice of analysis strategy: Fishers exact test. This
analysis does not stratify by trial but treats the whole 10 trials as one study. Therefore the benefit of randomisation is lost, resulting in a
non-randomised comparison. To confirm that they did indeed use Fishers exact test two analyses where the actual P value is reported
can be checked.
Hospitalisations: 18/1063 versus 9/1350 P = 0.019 (Kaiser et al report P = 0.02)
LRTC in high risk patients: 74/401 versus 45/368 P = 0.021 (Kaiser et al report P = 0.02)
The resulting P values are the same (to two decimal places) therefore it is highly likely that they did indeed use Fishers exact test to
compare the overall groups (without stratification). Normally in a meta-analysis of individual RCTs, separate comparisons by trial are
made and then combined in an appropriate way to obtain the overall effect of treatment. A “correct” analysis is especially important in
this case because of the following facts reported in Kaiser et al:
1. The populations studied in each trial are different: healthy adults in four studies; elderly patients in four studies, and adults with
chronic obstructive airways disease (COAD) in two studies.
2. Overall there are more oseltamivir patients compared to placebo patients (2023 versus 1541) hence at least one trial did not have
a 1:1 allocation ratio.
3. The trials had different proportions of influenza infected patients (ranging from 50% to 73%).
4. Overall there were more high risk patients in the placebo group compared to the oseltamivir group (38% versus 27%) hence
(overall) groups are not comparable.
The Kaiser et al study did not report the numbers of patients randomised to the two groups for each of the 10 trials; they just reported
overall numbers. The following hypothetical meta-analysis of two trials illustrates why a correct analysis is critical.
Table of proportions of adverse events by (hypothetical) trial
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Trial number
Adverse Events
Treatment Placebo Total
Trial 1 (high risk patients) 50/100 (50%) 50/100 (50%) 100/200 (50%)
Trial 2 (low risk patients) 10/200 (5%) 4/80 (5%) 14/280 (5%)
Total 60/300 (20%) 54/180 (30%)
This meta-analysis shows two trials with no effect. However, the two trials have recruited much different patient groups (e.g. elderly
patients in trial 1 and the general population in trial 2). Also trial 2 has not allocated with a ratio of 1:1 (as in at least one of the
Kaiser et al trials). Like the Kaiser et al study there is a higher proportion of high risk patients overall in the placebo group (56% versus
33%). A naïve analysis that does not stratify by trial (Fishers exact test) shows a significant difference between treatment (20% events)
and placebo (30% events) with P = 0.01 (odds ratio = 0.58). Conversely an analysis that stratifies for trial (logistic regression) shows
no difference (P = 1.0, odds ratio = 1.0). In the case of the Kaiser et al data, a random-effects meta-analysis that takes into account
heterogeneity between trials may be most appropriate.
Note that the hypothetical example shown above is “extreme”. However, it does illustrate what could happen with a naïve analysis that
does not stratify by trial. The important point is that with a naïve analysis there is no guarantee of an unbiased estimate of treatment
effect or a realistic 95% confidence interval and P value.
Tom Jefferson, Mark Jones, Peter Doshi, Chris Del Mar, Liz Dooley
Date of inclusion: 10 November 2009
Contributors
Keiji Hayashi
Date of inclusion: 16 July 2009
Neuraminidase inhibitors for preventing and treating influenza in healthy adults, 30 July 2009
Summary
The last sentence under Results, preceding Discussion is: ’Finally, use of relief medications and antibiotics is unaffected by assumption
of NIs (OR 0.81, 95% CI 0.59 to 1.12).’ Here ’assumption’ makes no sense, so should the words in bold be ’consumption of an NI’?
Submitter agrees with default conflict of interest statement: I certify that I have no affiliations with or involvement in any organization
or entity with a financial interest in the subject matter of my feedback.
Reply
Thanks you, we have re-written this part of the review to make it clearer.
Tom Jefferson, Mark Jones, Peter Doshi, Chris Del Mar, Liz Dooley
Date of inclusion: 15 November 2009
Contributors
Andrew Herxheimer
Date of inclusion: 30 July 2009
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WH A T ’ S N E W
Last assessed as up-to-date: 6 August 2009.
Date Event Description
29 September 2010 Amended Published notes section updated to explain to readers why this review will not be updated.
H I S T O R Y
Protocol first published: Issue 1, 1999
Review first published: Issue 2, 1999
Date Event Description
12 November 2009 New citation required and conclusions have changed 1.We excluded two new studies (Blumentals 2007 and
Toovey 2008).
2. We now study pharmacovigilance data.
3. We excluded a previously included study (Kaiser
2003) as we could not answer the Hayashi comment
by reconstructing the Kaiser 2003 data set. Hayashi
promptedus tomore carefully evaluate theKaiser2003
study. More critical evaluation of it leads essentially to
a retraction of our 2006 and 2009 updates of this re-
view. It results in changed conclusions: excluding the
Kaiser 2003 data, and failing to identify sufficient toxi-
city data frompharmacovigilance sources, we conclude
that there is insufficient evidence to describe the ef-
fects of oseltamivir on complications of influenza and
its toxicity.
4. There is a change in authors of the review team.
5. The review was published in a print journal in a
shortened form, December 2009 (Jefferson 2009e).
7 August 2009 New search has been performed Safety/adverse effects searches conducted.
30 July 2009 Feedback has been incorporated Feedback added to review.
16 July 2009 Feedback has been incorporated Feedback added to review.
14 July 2009 New search has been performed Effectivess searches conducted.
20 May 2008 New search has been performed Searches conducted in May 2008. For this update
we assessed 688 possible studies, retrieved 17 and ex-
cluded all of them.Our conclusion did not change but
we found non-comparative phase IV evidence from a
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(Continued)
thorough review of the evidence on harms by Hama
which we mentioned in the Discussion section. Up-
dated review published in issue 2, 2009.
29 April 2008 Amended Converted to new review format.
19 May 2006 New citation required and conclusions have changed Substantive amendment published in Issue 3, 2006.
13 October 2005 New search has been performed Searches conducted in October 2005. We completely
revised the text and added a section on evidence from
an avian influenza epidemic that took place in the
Netherlands in 2003 and claimed one life. We also
added a section on post-exposure prophylaxis (PEP)
. We dropped studies looking at the effects of neu-
raminidase inhibitors (NIs) on experimental influenza
cases (that is to say, on subjects who had been delib-
erately infected as part of an experiment) and con-
centrated on the now numerous studies of naturally-
acquired influenza cases. The terms ”laboratory-con-
firmed influenza“ and ”clinically confirmed influenza“
have been changed for the more correct terms ”in-
fluenza“ and ”influenza-like-illness“ (ILI). We believe
these words to reflect the difference between real in-
fluenza (caused by influenza A and B viruses) and
what is colloquially known as ”the flu“. The two are
rarely clinically distinguishable in real-time unless a
very good surveillance apparatus is in place, as in most
of the trials in our review. Updated review published
in Issue 3, 2006.
24 February 1999 New search has been performed Review first published in Issue 2, 1999.
C O N T R I B U T I O N S O F A U T H O R S
For the 2009 update Tom Jfferson (TOJ) applied inclusion criteria.
Liz Dooley (ED) and TOJ independently read all titles and studies retrieved in the search and applied inclusion criteria. All authors
except Ruth Foxlee (RF) reappraised and investigated extracted data while Chris Del Mar (CDM) supervised the process and arbitrated
when necessary.
Mark Jones (MJ) and Peter Doshi (PD) checked and transformed data and supervised the revised meta-analysis.
TOJ and CDM edited the text and together with ED, MJ and PD, contributed to the final draft.
RF developed and conducted the searches for adverse effects studies.
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D E C L A R A T I O N S O F I N T E R E S T
In 1998 to 1999 Tom Jefferson was an ad hoc consultant for Hoffman LaRoche Ltd. In 2008 to 2009 Chris Del Mar provided expert
advice to Glaxo Smith Kline about vaccination against acute otitis media.
S O U R C E S O F S U P P O R T
Internal sources
• The authors’ own institutions (2005 update), Italy.
• The author’s own institutions (2005 update), Australia.
External sources
• National Instiutue of Health Research (NIHR), UK.
Competitive grant awarded through the Cochrane Collaboration
• National Health and Medical Research Council (NHMRC), Australia.
Competitive grant awarded to Chris Del Mar and Tom Jefferson, 2009
N O T E S
This review will not be updated as the review authors are working with the authors of the Cochrane Review ’Neuraminidase inhibitors
for preventing and treating influenza in children’ to write an amalgamated review ’Neuraminidase inhibitors for preventing and treating
influenza in healthy adults and children’. This new protocol is expected to be published on The Cochrane Library by the end of 2010.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antiviral Agents [adverse effects; ∗therapeutic use]; Enzyme Inhibitors [adverse effects; ∗therapeutic use]; Influenza, Human [∗drug
therapy; ∗prevention & control]; Neuraminidase [∗antagonists & inhibitors]; Oseltamivir [adverse effects; therapeutic use]; Post-
Exposure Prophylaxis; Randomized Controlled Trials as Topic; Zanamivir [adverse effects; therapeutic use]
MeSH check words
Adult; Humans
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